{"title":"Farmaci Lassativi per la Stitichezza","description":"\u003cp\u003eLassativi da banco per la stitichezza occasionale: stimolanti in compresse e gocce, osmotici in bustine a base di macrogol e lattulosio, lassativi di massa con fibre, supposte di glicerolo e clismi pronti all’uso ad azione rapida. Formati per adulti e per bambini, da usare per periodi brevi. Spedizione veloce in 24\/48 ore.\u003c\/p\u003e","products":[{"product_id":"pursennid-30-compresse-lassative-12-mg","title":"Pursennid 40 Laxative Tablets 12 mg","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term treatment of occasional constipation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne coated tablet contains: - Active ingredient: sennosides A + B (as calcium salts) 12 mg. - Excipients with known effects: lactose monohydrate; anhydrous glucose; sucrose. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eLactose monohydrate\u003c\/b\u003e; stearic acid; talc; corn starch; \u003cb\u003eanhydrous glucose\u003c\/b\u003e; \u003cb\u003esucrose\u003c\/b\u003e; gum arabic; anhydrous colloidal silica; titanium dioxide; cetyl palmitate.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Contraindicated if the following medical conditions exist: - Inflammatory diseases of the digestive system (i.e. Crohn's disease, ulcerative colitis, liver disease, peritonitis and inflammatory intestinal diseases); - Irritation or obstruction of the gastrointestinal tract (i.e. spastic constipation, obstruction of the ileum\/preileum, cramps and pain, nausea, vomiting and colic); - Abdominal symptoms that may be due to an undiagnosed underlying condition, such as acute intestinal conditions that may require surgery (i.e. acute diverticulitis, appendicitis and massive diarrhea); - states of severe dehydration, with loss of water and electrolytes, especially hypokalemia. Contraindicated in children under 10 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eDosage\u003c\/b\u003e Adults and children over 12 years of age: 2-4 coated tablets per day. Children between 10 and 12 years: 1-2 coated tablets per day. After a short period of treatment without appreciable results, consult your doctor. The correct dose is the minimum sufficient to produce an easy evacuation of loose stools. It is advisable to initially use the minimum doses provided. When necessary, the dose can then be increased, but without ever exceeding the maximum indicated. \u003cb\u003ePediatric population\u003c\/b\u003e Contraindicated in children under 10 years of age. \u003cb\u003eMethod of administration\u003c\/b\u003e Take preferably in the evening. The action of Pursennid occurs after 6-12 hours. Administered in the evening, the effect of Pursennid appears the following morning. Laxatives should be used as infrequently as possible and for no longer than seven days. Use for longer periods of time requires a doctor's prescription after adequate evaluation of the individual case. Swallow together with an adequate quantity of water (a large glass). A diet rich in liquids favors the effect of the medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe established dose must not be exceeded. Prolonged indiscriminate use of laxatives can lead to addiction and a deterioration of intestinal functions. The lowest effective dosage should be used to restore normal intestinal function. If no improvement has been achieved in the intestine, the dosage can be increased under medical supervision. Products containing senna and sennosides should only be used if a therapeutic effect cannot be achieved through a change in diet or the administration of bulking agents. The use of these drugs requires medical supervision: - if there are no positive effects following the treatment; - if use is prolonged beyond one week of treatment; - if symptoms persist or worsen; - after a laparotomy or abdominal surgery; - if a skin rash is present, because it can be a sign of hypersensitivity; - if nausea and vomiting are present, because these symptoms may be signs of a potential or existing intestinal blockage (ileus); - in children between 10 and 12 years old. \u003cu\u003eInformation relating to excipients\u003c\/u\u003e - Lactose: patients suffering from rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. - Glucose: patients suffering from rare problems of glucose-galactose malabsorption should not take this medicine. - Sucrose: patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eConcomitant use of other drugs that induce hypokalemia (i.e. diuretics, adrenocorticosteroids and licorice) may increase electrolyte imbalance. Hypokalemia (resulting from abuse of laxatives taken for a long time) enhances the action of cardiac glycosides and interferes with antiarrhythmic drugs, with other drugs that induce the return to sinus rhythm (quinidine) and with drugs that induce prolongation of the Q-T interval.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicine may cause mild abdominal discomfort such as abdominal pain, cramps, irritation of the colonic and gastric mucosa. Other effects such as dehydration, hypotension, fatigue, myopathies, stomach pain, hyponatremia, renal disorders, secondary hyperaldosteronism, hypocalcemia and hypomagnesemia have also been reported. These adverse reactions are usually reversible once you stop taking the laxative. Prolonged use or overdose of this drug may cause nausea, diarrhea with excessive loss of electrolytes, especially potassium (hypokalemia). There is also the possibility of developing megacolon. During treatment, a yellow-brownish coloration (pH-dependent) of the urine may occur due to metabolites, which has no clinical significance. Habituation has been reported after prolonged treatment. Adverse reactions are listed below by system organ class and frequency. Frequencies are defined as: \u003ci\u003every common\u003c\/i\u003e (≥ 1\/10), \u003ci\u003ecommon\u003c\/i\u003e (≥ 1\/100, \u0026lt; 1\/10); \u003ci\u003euncommon\u003c\/i\u003e (≥ 1\/1.000, \u0026lt; 1\/100); \u003ci\u003erare\u003c\/i\u003e (≥ 1\/10.000; \u0026lt; 1\/1.000); \u003ci\u003every rare\u003c\/i\u003e (\u003c 1\/10,000), or \u003ci\u003enot known\u003c\/i\u003e (frequency cannot be estimated from the available data). \u003cb\u003eTable 4-1 Undesirable effects in the post-marketing experience \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Hypersensitivity reactions (itching, urticaria, local or generalized rash).\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Megacolon.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Abdominal pain.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Diarrhoea.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Nausea.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Abdominal discomfort.\u003c\/p\u003e\n\u003cp\u003eNot known.\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Fatigue.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Drug tolerance.\u003c\/p\u003e\n\u003cp\u003ePathologies of the musculoskeletal system and connective tissue.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Myopathy.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Kidney problems.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Chromaturia.\u003c\/p\u003e\n\u003cp\u003eMetabolism and nutrition disorders.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Hyperaldosteronism.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Hypocalcemia.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Hypomagnesemia.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Dehydration.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Hypokalemia.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Hyponatremia.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Decreased blood electrolytes.\u003c\/p\u003e\n\u003cp\u003eVascular pathologies.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse event: Hypotension.\u003c\/p\u003e\n\u003cp\u003eThe adverse events listed above are based on spontaneous post-marketing reports and represent a less precise estimate of the incidence that would be obtained in clinical trials. \u003cb\u003ePediatric population\u003c\/b\u003e The same frequency, type and severity of adverse events are expected in children and adults. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSymptoms\u003c\/b\u003e The most important symptoms related to overdose\/excessive use are abdominal colic and severe diarrhea resulting in losses of fluids and electrolytes, which must be replaced. Diarrhea especially can cause potassium loss, which can lead to cardiac disorders and muscular asthenia, particularly when cardiac glycosides, diuretics, adrenocorticosteroids or licorice root are administered at the same time. \u003cb\u003eManagement\u003c\/b\u003e Treatment must be supportive with generous quantities of fluids. Electrolytes, especially potassium, should be monitored. This is especially important in the elderly. Chronic overdose of anthraquinone drugs can cause toxic hepatitis. Further treatment modalities should take into account clinical indications or poison control center recommendation, where available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e There are no adequate data on the use of sennosides in pregnant women. Animal studies have not shown reproductive toxicity. The potential risk for humans is unknown. Pregnant women should consult their doctor before taking this medicine. \u003cu\u003eBreastfeeding\u003c\/u\u003e Use during breastfeeding is not recommended as there are insufficient data on the excretion of the metabolites in breast milk. Small quantities of metabolites (rein) are excreted in breast milk. No laxative effect has been reported on breast-fed infants. \u003cu\u003eFertility\u003c\/u\u003e Preclinical studies with sennosides do not indicate particular risks for fertility at therapeutically relevant doses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicine has no or negligible influence on the ability to drive or use machinery.\u003c\/p\u003e","brand":"Gsk","offers":[{"title":"Default Title","offer_id":40207823732851,"sku":"004758025","price":12.28,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/glaxosmithkline-c-health-spa-pursennid-30-compresse-lassative-12-mg-farmacia-dottor-tili-1213792748.jpg?v=1767125872"},{"product_id":"glicerolo-carlo-erba-18-supposte-2250-mg","title":"Glycerol Carlo Erba 18 Suppositories 2250 mg.","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term treatment of occasional constipation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eGLYCEROL CARLO ERBA Early childhood 900 mg suppositories\u003c\/i\u003e An early childhood suppository contains: active ingredient: Glycerol 900 mg. \u003ci\u003eGLYCEROL CARLO ERBA Children 1375 mg\u003c\/i\u003e \u003ci\u003esuppositories\u003c\/i\u003e One children's suppository contains: active ingredient: Glycerol 1375 mg. \u003ci\u003eGLYCEROL CARLO ERBA Adults 2250 mg suppositories\u003c\/i\u003e An adult suppository contains: active ingredient: Glycerol 2250 mg. \u003ci\u003eGLYCEROL CARLO ERBA Children 2.25 g rectal solution\u003c\/i\u003e Each single-dose container contains: active ingredient: Glycerol 2.25 g. \u003ci\u003eGLYCEROL CARLO ERBA Adults 6.75 g rectal solution\u003c\/i\u003e Each single-dose container contains: active ingredient: Glycerol 6.75 g. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSuppositories\u003c\/u\u003e: sodium stearate; sodium carbonate. \u003cu\u003eRectal solution\u003c\/u\u003e: chamomile fluid extract; mauve fluid extract; wheat starch; purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• hypersensitivity to the active ingredient or to any of the excipients; • acute abdominal pain or pain of unknown origin; • nausea or vomiting; • intestinal obstruction or stricture; • rectal bleeding of unknown origin; • acute hemorrhoidal crisis with pain and bleeding; • severe state of dehydration.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe correct dose is the minimum sufficient to produce an easy evacuation. It is advisable to initially use the minimum doses provided. \u003cu\u003eDosage\u003c\/u\u003e \u003cb\u003eSuppositories\u003c\/b\u003e: \u003cu\u003eAdults\u003c\/u\u003e: 1 adult suppository as needed, for a maximum of 1 or 2 administrations per day. \u003ci\u003ePediatric population\u003c\/i\u003e \u003cu\u003eAdolescents (12 – 18 years)\u003c\/u\u003e: 1 adult suppository as needed, for a maximum of 1 or 2 administrations per day. \u003cu\u003eChildren aged 2 – 11 years\u003c\/u\u003e: 1 suppository for children as needed, for a maximum of 1 or 2 administrations per day. \u003cu\u003eChildren aged between 1 month and 2 years\u003c\/u\u003e: 1 early childhood suppository as needed, for a maximum of 1 or 2 administrations per day. \u003cb\u003eRectal solution\u003c\/b\u003e: \u003cu\u003eAdults\u003c\/u\u003e: 1 single-dose container for adults as needed, for a maximum of 1 or 2 administrations per day. \u003ci\u003ePediatric population\u003c\/i\u003e \u003cu\u003eAdolescents (12 – 18 years)\u003c\/u\u003e: 1 single-dose container for adults as needed, for a maximum of 1 or 2 administrations per day. \u003cu\u003eChildren aged between 6 – 11 years\u003c\/u\u003e: 1 or 2 single-dose containers for children as needed, for a maximum of 1 or 2 administrations per day. \u003cu\u003eChildren aged between 2 – 6 years\u003c\/u\u003e: 1 single-dose container for children as needed for a maximum of 1 or 2 administrations per day. \u003cu\u003eMethod of administration\u003c\/u\u003e \u003cu\u003eSuppositories\u003c\/u\u003e: Remove the suppository from its container and then, if necessary, moisten it to facilitate rectal introduction. If the suppositories appear softened, immerse the containers in cold water before opening them. \u003cu\u003eRectal solution\u003c\/u\u003e: To remove the safety cannula cover from the single-dose container, place your index finger and thumb on the round ring placed above the bellows and, with the other hand, bend the cannula cover until it detaches from the body of the container. During the operation, never grasp the bellows, otherwise the medicine would leak before use. It may be useful to lubricate the cannula with a drop of the solution itself, before introducing it into the rectum and pressing the bellows. Extract the cannula while holding down the bellows. Each container must be used for a single administration only; any residual medicine must be discarded. In children under twelve years of age the medicine can only be used after consulting a doctor. Laxatives should be used as infrequently as possible and for no longer than seven days (see section 4.4). A diet rich in liquids favors the effect of the medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore in the original packaging to protect the medicine from humidity and away from direct sources of heat.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLaxatives should be used as infrequently as possible and for no longer than seven days. Use for longer periods of time requires a doctor's prescription after adequate evaluation of the individual case. The treatment of chronic or recurrent constipation always requires the intervention of a doctor for diagnosis, prescription of drugs and monitoring during the course of therapy. It is also advisable for elderly people or those in poor health to consult their doctor before using the medicine. Abuse of laxatives can cause persistent diarrhea with consequent loss of water, mineral salts (especially potassium) and other essential nutritional factors. In more serious cases of abuse, the onset of dehydration or hypokalemia is possible, which can cause cardiac or neuromuscular dysfunction, especially in case of simultaneous treatment with cardiac glycosides, diuretics or corticosteroids. The abuse of laxatives, especially contact laxatives (stimulant laxatives), can cause dependence (and, therefore, possible need to progressively increase the dosage), chronic constipation and loss of normal intestinal functions (intestinal atony). In episodes of constipation, it is recommended first of all to correct eating habits by integrating the daily diet with an adequate intake of fiber and water. When using laxatives it is advisable to drink at least 6-8 glasses of water or other liquids a day to help soften the stool.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo specific interaction studies have been performed.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects observed during treatment in clinical studies and integrated with those collected during post-marketing experience are listed in the table below according to System Organ Class (using MedDRA terminology) and according to the following frequency: Very common ≥1\/10; Common ≥1\/100, \u003c1\/10; Uncommon ≥1\/1,000, \u003c1\/100; Rare ≥1\/10,000, \u003c1\/1,000; Very rare \u003c1\/10,000; Not known (frequency cannot be estimated from the available data). The available data are insufficient to establish the frequency of the individual effects listed.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eNot known: Cramp-like pain in the abdomen*; abdominal colic, diarrhea**, anal irritation.\u003c\/p\u003e\n\u003cp\u003e*usually isolated ** with loss of fluids and electrolytes Isolated cramping pain or abdominal colic and diarrhea are more frequent in cases of severe constipation. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at \"www.agenziafarmaco.gov.it\/it\/responsabili\".\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported. In any case, excessive doses (abuse of laxatives – frequent or prolonged use or with excessive doses) can cause abdominal pain and persistent diarrhea with consequent loss of water, mineral salts (especially potassium) and other essential nutritional factors. Fluid and electrolyte losses must be replaced. Electrolyte imbalances are characterized by the following symptoms: thirst, vomiting, weakness, edema, bone pain (osteomalacia) and hypoalbuminemia. In more serious cases, the onset of dehydration or hypokalaemia is possible which can cause cardiac or neuromuscular dysfunction, especially in the case of simultaneous treatment with cardiac glycosides, diuretics or corticosteroids. The abuse of laxatives, especially contact laxatives (stimulant laxatives), can cause dependence (and, therefore, possible need to progressively increase the dosage), chronic constipation and loss of normal intestinal functions (intestinal atony).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo adequate and well-controlled studies have been carried out on the use of the medicine during pregnancy or breastfeeding. Although there are no obvious contraindications to the use of the medicine during pregnancy and breastfeeding, it is recommended to take the medicine only if necessary and under medical supervision.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGlycerol has no influence on the ability to drive vehicles and use machines. However, it is possible that side effects may occur during treatment, therefore it is good to know the reaction to the drug before driving vehicles or using machinery.\u003c\/p\u003e","brand":"Carlo Erba","offers":[{"title":"Default Title","offer_id":40207823896691,"sku":"029651039","price":6.5,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/carlo-erba-otc-srl-glicerolo-carlo-erba-18-supposte-2250-mg-farmacia-dottor-tili-1213792744.jpg?v=1767125952"},{"product_id":"verolax-ad-rettale-6-clismi-6-75g","title":"Verolax AD Rectal 6 Enemas 6.75g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eConstipation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eVerolax “6.75 g Adults Rectal Solution” 6 Single-dose Containers 9 G\u003c\/i\u003e: Each 9G single-dose container contains: \u003ci\u003eActive ingredient\u003c\/i\u003e: glycerin 6.75 g \u003ci\u003eVerolax “2.25 g Children Rectal Solution” 6 Single-dose Containers 3 G\u003c\/i\u003e: Each 3G single-dose container contains: \u003ci\u003eActive ingredient\u003c\/i\u003e: glycerin 2.25 g \u003ci\u003eVerolax “2.25 g Adult Suppositories” 18 Suppositories\u003c\/i\u003e:Each adult suppository contains: \u003ci\u003eActive ingredient\u003c\/i\u003e: glycerin 2.25 g \u003ci\u003eVerolax “1,375 g Children Suppositories” 18 Suppositories\u003c\/i\u003e: Each children's suppository contains: \u003ci\u003eActive ingredient\u003c\/i\u003e: glycerin 1.375 g \u003ci\u003eVerolax “0.675 g Infant Suppositories” 12 Suppositories\u003c\/i\u003e: Each infant suppository contains: \u003ci\u003eActive ingredient\u003c\/i\u003e: glycerin 0.675 g\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eRectal solution for adults and children:\u003c\/i\u003e Mallow fluid extract; Chamomile fluid extract; Wheat starch; Purified water. \u003ci\u003eSuppositories Adults, Children, Infants:\u003c\/i\u003e Sodium stearate, Sodium carbonate.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIndividual hypersensitivity confirmed towards the product. Anorectal diseases, hemorrhagic rectocolitis and inflammation of hemorrhoids. \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eRectal solution:\u003c\/i\u003e 1 or 2 single-dose containers in 24 hours. In case of stubborn constipation, no more than 2 doses can be introduced into the rectum at the same time. \u003ci\u003eSuppositories:\u003c\/i\u003e 1 suppository as needed. Do not exceed the recommended doses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo special precautions for storage.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe continuous use of laxatives can cause addiction or damage of various types. Do not use laxatives if abdominal pain, nausea and vomiting are present. If constipation is stubborn, consult your doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo interactions with other drugs have been found. \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe only effects that may be encountered are irritative, at the level of the rectal area. These are usually mild forms, which do not require medical intervention.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known symptoms of overdose.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBased on its chemical-physical properties, rectal glycerin can be usefully used during pregnancy or the puerperium.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTaking the drug does not alter the ability to drive or use machines.\u003c\/p\u003e","brand":"Angelini","offers":[{"title":"Default Title","offer_id":40207824453747,"sku":"026525055","price":5.21,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-verolax-ad-rettale-6-clismi-6-75g-farmacia-dottor-tili-1254215759.jpg?v=1786737460"},{"product_id":"lattulosio-sand-sciroppo-180-ml","title":"Lactulose Sand Syrup 180 ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term treatment of occasional constipation. \u003cu\u003eAdults:\u003c\/u\u003e occasional constipation; adjuvant in intestinal bacterial diseases caused by coliform germs (Salmonella, Shigella, etc.) \u003cu\u003eChildren and infants:\u003c\/u\u003e constipation; treatment of putrefactive syndromes due to eating disorders; as a corrective to the infant's diet, especially in the transition from maternal to artificial breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003e66.7% syrup, 180 ml bottle\u003c\/u\u003e 100 ml of syrup contains 66.7 g of lactulose Excipients with known effect: 100 ml of syrup contains 0.118 g of sodium benzoate. For the complete list of excipients see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003esodium benzoate; purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Laxatives are contraindicated in subjects with acute abdominal pain or pain of unknown origin, nausea or vomiting, intestinal obstruction or stenosis, rectal bleeding of unknown origin, severe dehydration. Contraindicated in subjects suffering from galactosemia. Generally contraindicated in pediatric age (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDosage \u003cu\u003eAdults: \u003c\/u\u003ethe average daily dosage is 10-15 g in two administrations. This dosage can be doubled or halved depending on the individual response or clinical picture. Pediatric population \u003cu\u003eChildren:\u003c\/u\u003e from 2.5 to 10 g\/day, even in a single administration, depending on the age and severity of the case. \u003cu\u003eInfants:\u003c\/u\u003e on average 2.5 g per day. The correct dose is the minimum sufficient to produce an easy evacuation of loose stools. It is advisable to initially use the minimum doses provided. When necessary, the dose can then be increased, but without ever exceeding the maximum indicated. Take preferably in the evening. Laxatives should be used as infrequently as possible and for no longer than seven days. Use for longer periods of time requires a doctor's prescription after adequate evaluation of the individual case. Swallow together with an adequate quantity of water (a large glass). A diet rich in liquids favors the effect of the medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSpecial warnings\u003c\/u\u003e Lactulose is absorbed to a very small extent and has no caloric value. However, in addition to lactulose, Lactulose Sandoz also contains galactose, lactose and small quantities of other sugars. This must be taken into account in the treatment of diabetic patients and in patients following low-calorie diets. Abuse of laxatives (frequent or prolonged use or with excessive doses) can cause persistent diarrhea with consequent loss of water, mineral salts (especially potassium) and other essential nutritional factors. In more severe cases, the onset of dehydration or hypokalemia is possible which can cause cardiac or neuromuscular dysfunction, especially in the case of simultaneous treatment with cardiac glycosides, diuretics or corticosteroids. The abuse of laxatives, especially contact laxatives (stimulant laxatives), can cause dependence (and, therefore, possible need to progressively increase the dosage), chronic constipation and loss of normal intestinal functions (intestinal atony). \u003cu\u003ePrecautions for use\u003c\/u\u003e Do not use the medicine if abdominal pain, nausea and vomiting are present. If constipation is stubborn, consult a doctor. In patients who present disorders caused by excessive intestinal meteorism it is advisable to start treatment with the minimum doses indicated; these doses can be gradually increased in relation to the patient's response. In children under 12 years of age the medicine can only be used after consulting a doctor. The treatment of chronic or recurrent constipation always requires the intervention of a doctor for diagnosis, prescription of medicines and monitoring during the course of therapy. Consult your doctor when the need for the laxative derives from a sudden change in previous intestinal habits (frequency and characteristics of evacuations) that lasts for more than two weeks or when the use of the laxative fails to produce effects. It is also advisable for elderly people or those in poor health to consult their doctor before using the medicine. \u003cb\u003e \u003cu\u003eImportant information about some excipients\u003c\/u\u003e \u003c\/b\u003e Lactulose Sandoz contains 26.4 mg of sodium benzoate per average daily dose equivalent to 0.14 mg\/ml. Sodium benzoate may increase jaundice (yellowing of the skin and eyes) in newborns up to 4 weeks of age. The increase in bilirubin following its detachment from albumin can increase neonatal jaundice which can progress to kernicterus (deposits of unconjugated bilirubin in the brain tissue). Lactulose Sandoz contains less than 1 mmol (23 mg) sodium per dose, i.e. essentially 'sodium-free'.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBroad-spectrum antibacterial agents, administered orally at the same time as lactulose, can reduce degradation, limiting the possibility of acidification of the intestinal contents and consequently the therapeutic efficacy. Laxatives can reduce the residence time in the intestine, and therefore the absorption, of other medicines administered simultaneously orally. Therefore, avoid ingesting laxatives and other medicines at the same time: after taking a medicine, leave an interval of at least 2 hours before taking the laxative.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders: Occasionally: isolated cramping pain or abdominal colic, more frequent in cases of severe constipation. Frequency not known: flatulence. Immune system disorders: Frequency not known: hypersensitivity reactions. Skin and subcutaneous tissue disorders: Frequency not known: rash, itching, urticaria. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eExcessive doses can cause abdominal pain and diarrhea; the resulting losses of fluids and electrolytes must be replaced. Also see what is reported in the paragraph “Special warnings and precautions for use” regarding the abuse of laxatives.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no adequate and well-controlled studies on the use of the medicine during pregnancy or breastfeeding. Therefore the medicine must be used only if necessary, under the direct supervision of the doctor, after having evaluated the expected benefit for the mother in relation to the possible risk for the fetus or infant.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLactulose sandoz does not alter the ability to drive and use machines.\u003c\/p\u003e","brand":"Sandoz","offers":[{"title":"Default Title","offer_id":40207839035507,"sku":"027668019","price":7.49,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sandoz-lattulosio-sand-sciroppo-180-ml-farmacia-dottor-tili-1254215794.jpg?v=1786737131"},{"product_id":"laevolac-sciroppo-stitichezza-180-ml","title":"Laevolac Constipation Syrup 180 ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term treatment of occasional constipation in adults and children\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLAEVOLAC 66.7 g\/100 ml syrup 100 ml of syrup contain: active ingredient: lactulose 66.7 g. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSyrup: none.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to lactulose or to any of the excipients listed in section 6.1. • Acute abdominal pain or pain of unknown origin, • nausea or vomiting, • intestinal obstruction or stenosis, • rectal bleeding of unknown origin, • severe dehydration.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eDosage\u003c\/i\u003e The correct dose is the minimum sufficient to produce an easy evacuation of loose stools. It is recommended to initially use the minimum doses envisaged. Do not exceed the maximum recommended daily dose. \u003cb\u003eAdults \u003c\/b\u003e The recommended dose is 15 - 30 ml (corresponding to 10 - 20 g of lactulose) to be taken in one or two administrations per day. When necessary the dose can be increased. The maximum daily dose is 45 ml (corresponding to 30 g of lactulose). \u003cb\u003eAdolescents and children ≥ 10 years \u003c\/b\u003e The recommended dose is 15 ml (corresponding to 10 g of lactulose) to be taken in one or two doses per day. The maximum daily dose is 15 ml. \u003cb\u003eChildren 5 - \u003c 10 years\u003c\/b\u003e The recommended dose is 10 ml (corresponding to 6.67 g of lactulose) to be taken in one or two administrations per day. The maximum daily dose is 10 ml. \u003cb\u003eChildren \u003e1 - \u003c 5 years\u003c\/b\u003e The recommended dose is 5 ml (corresponding to 3.33 g of lactulose) to be taken in one or two administrations per day. The maximum daily dose is 5 ml. \u003cb\u003eChildren 1 month - 1 year\u003c\/b\u003e The recommended dose is 2.5 ml (corresponding to 1.66 g of lactulose) to be taken in a single administration in the evening. The maximum daily dose is 2.5 ml. \u003ci\u003eDuration of treatment\u003c\/i\u003e Laxatives should be used as infrequently as possible and for no longer than seven days. The prescription for prolonged use must be established after adequate clinical evaluation. \u003ci\u003eMethod of administration\u003c\/i\u003e In case of single daily administration, take preferably in the evening. If the dose is divided into two administrations per day, take preferably in the morning and in the evening.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSyrup: Store below 25°C. Shelf life after first opening the bottle: 12 months if stored at temperatures below 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eWarnings:\u003c\/u\u003e Abuse of laxatives (frequent or prolonged use or with excessive doses) can cause persistent diarrhea with consequent loss of water, mineral salts (especially potassium) and other essential nutritional factors. In more severe cases, the onset of dehydration or hypokalemia is possible which can cause cardiac or neuromuscular dysfunction, especially in case of simultaneous treatment with cardiac glycosides, diuretics or corticosteroids. The abuse of laxatives, especially contact ones (stimulant laxatives), can cause addiction (possible need to progressively increase the dosage), chronic constipation and loss of normal intestinal functions (intestinal atony). If diarrhea appears, therapy should be suspended. LAEVOLAC contains galactose and lactose. Patients with rare hereditary problems of galactose intolerance, e.g. galactosemia, or glucose-galactose malabsorption, should not take this medicine. LAEVOLAC contains fructose. The additive effect of co-administration of medicinal products containing fructose (or sorbitol) and dietary intake of fructose (or sorbitol) should be considered.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLaxatives can reduce the residence time in the intestine, and therefore the absorption, of other drugs administered simultaneously orally. Avoid ingesting laxatives and other medicines at the same time: after taking a medicine, leave an interval of at least 2 hours before taking the laxative. Laevolac may lead to increased toxicity of digitalis due to potassium depletion. A synergistic effect with neomycin is possible. Broad-spectrum antibacterial agents, administered orally at the same time as lactulose, can reduce its degradation, limiting the possibility of acidification of the intestinal contents and, consequently, the therapeutic efficacy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following are the side effects organized according to the MedDRA System Organ classification. The frequency is defined as follows: very common (≥1\/10), common (≥1\/100 to \u003c1\/10), uncommon (≥1\/1000 to \u003c1\/100), rare (≥1\/10,000 to \u003c1\/1000), very rare (\u003c1\/10,000), not known (the frequency cannot be estimated from the available data).\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Very common. Side effect: Abdominal pain, flatulence.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Common. Side effect: Abdominal distention, urgency of evacuation, diarrhea, nausea.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Uncommon. Side effect: Vomiting.\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and conditions relating to the administration site - Frequency: Common. Side effect: Reduced appetite.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Common. Side effect: Headache.\u003c\/p\u003e\n\u003cp\u003eMetabolism and nutrition disorders - Frequency: Not known. Side effect: Electrolyte depletion.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Frequency: Not known. Side effect: Hypersensitivity reactions\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Not known. Side effect: Skin rash, itching, urticaria.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eExcessive doses can cause abdominal pain and diarrhea, in which case treatment should be suspended and the resulting losses of fluids and electrolytes must be replenished.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no adequate and well-controlled studies on the use of the medicine during pregnancy or during breastfeeding. The use of LAEVOLAC should be considered only in case of actual need and if the expected benefit for the mother outweighs the risk for the child.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLaevolac does not alter the ability to drive and use machines.\u003c\/p\u003e","brand":"Chiesi","offers":[{"title":"Default Title","offer_id":46369303200071,"sku":"029565013","price":9.69,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/chiesi-farmaceutici-spa-laevolac-sciroppo-stitichezza-180-ml-farmacia-dottor-tili-1213792502.webp?v=1767131379"},{"product_id":"glicerolo-carlo-erba-6-microclismi-soluzione-rettale-6-75g","title":"Glycerol Carlo Erba 6 Microenemas Rectal Solution 6,75g.","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term treatment of occasional constipation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eGLYCEROL CARLO ERBA Early childhood 900 mg suppositories\u003c\/i\u003e An early childhood suppository contains: active ingredient: Glycerol 900 mg. \u003ci\u003eGLYCEROL CARLO ERBA Children 1375 mg\u003c\/i\u003e \u003ci\u003esuppositories\u003c\/i\u003e One children's suppository contains: active ingredient: Glycerol 1375 mg. \u003ci\u003eGLYCEROL CARLO ERBA Adults 2250 mg suppositories\u003c\/i\u003e An adult suppository contains: active ingredient: Glycerol 2250 mg. \u003ci\u003eGLYCEROL CARLO ERBA Children 2.25 g rectal solution\u003c\/i\u003e Each single-dose container contains: active ingredient: Glycerol 2.25 g. \u003ci\u003eGLYCEROL CARLO ERBA Adults 6.75 g rectal solution\u003c\/i\u003e Each single-dose container contains: active ingredient: Glycerol 6.75 g. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSuppositories\u003c\/u\u003e: sodium stearate; sodium carbonate. \u003cu\u003eRectal solution\u003c\/u\u003e: chamomile fluid extract; mauve fluid extract; wheat starch; purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• hypersensitivity to the active ingredient or to any of the excipients; • acute abdominal pain or pain of unknown origin; • nausea or vomiting; • intestinal obstruction or stricture; • rectal bleeding of unknown origin; • acute hemorrhoidal crisis with pain and bleeding; • severe state of dehydration.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe correct dose is the minimum sufficient to produce an easy evacuation. It is advisable to initially use the minimum doses provided. \u003cu\u003eDosage\u003c\/u\u003e \u003cb\u003eSuppositories\u003c\/b\u003e: \u003cu\u003eAdults\u003c\/u\u003e: 1 adult suppository as needed, for a maximum of 1 or 2 administrations per day. \u003ci\u003ePediatric population\u003c\/i\u003e \u003cu\u003eAdolescents (12 – 18 years)\u003c\/u\u003e: 1 adult suppository as needed, for a maximum of 1 or 2 administrations per day. \u003cu\u003eChildren aged 2 – 11 years\u003c\/u\u003e: 1 suppository for children as needed, for a maximum of 1 or 2 administrations per day. \u003cu\u003eChildren aged between 1 month and 2 years\u003c\/u\u003e: 1 early childhood suppository as needed, for a maximum of 1 or 2 administrations per day. \u003cb\u003eRectal solution\u003c\/b\u003e: \u003cu\u003eAdults\u003c\/u\u003e: 1 single-dose container for adults as needed, for a maximum of 1 or 2 administrations per day. \u003ci\u003ePediatric population\u003c\/i\u003e \u003cu\u003eAdolescents (12 – 18 years)\u003c\/u\u003e: 1 single-dose container for adults as needed, for a maximum of 1 or 2 administrations per day. \u003cu\u003eChildren aged between 6 – 11 years\u003c\/u\u003e: 1 or 2 single-dose containers for children as needed, for a maximum of 1 or 2 administrations per day. \u003cu\u003eChildren aged between 2 – 6 years\u003c\/u\u003e: 1 single-dose container for children as needed for a maximum of 1 or 2 administrations per day. \u003cu\u003eMethod of administration\u003c\/u\u003e \u003cu\u003eSuppositories\u003c\/u\u003e: Remove the suppository from its container and then, if necessary, moisten it to facilitate rectal introduction. If the suppositories appear softened, immerse the containers in cold water before opening them. \u003cu\u003eRectal solution\u003c\/u\u003e: To remove the safety cannula cover from the single-dose container, place your index finger and thumb on the round ring placed above the bellows and, with the other hand, bend the cannula cover until it detaches from the body of the container. During the operation, never grasp the bellows, otherwise the medicine would leak before use. It may be useful to lubricate the cannula with a drop of the solution itself, before introducing it into the rectum and pressing the bellows. Extract the cannula while holding down the bellows. Each container must be used for a single administration only; any residual medicine must be discarded. In children under twelve years of age the medicine can only be used after consulting a doctor. Laxatives should be used as infrequently as possible and for no longer than seven days (see section 4.4). A diet rich in liquids favors the effect of the medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore in the original packaging to protect the medicine from humidity and away from direct sources of heat.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLaxatives should be used as infrequently as possible and for no longer than seven days. Use for longer periods of time requires a doctor's prescription after adequate evaluation of the individual case. The treatment of chronic or recurrent constipation always requires the intervention of a doctor for diagnosis, prescription of drugs and monitoring during the course of therapy. It is also advisable for elderly people or those in poor health to consult their doctor before using the medicine. Abuse of laxatives can cause persistent diarrhea with consequent loss of water, mineral salts (especially potassium) and other essential nutritional factors. In more serious cases of abuse, the onset of dehydration or hypokalemia is possible, which can cause cardiac or neuromuscular dysfunction, especially in case of simultaneous treatment with cardiac glycosides, diuretics or corticosteroids. The abuse of laxatives, especially contact laxatives (stimulant laxatives), can cause dependence (and, therefore, possible need to progressively increase the dosage), chronic constipation and loss of normal intestinal functions (intestinal atony). In episodes of constipation, it is recommended first of all to correct eating habits by integrating the daily diet with an adequate intake of fiber and water. When using laxatives it is advisable to drink at least 6-8 glasses of water or other liquids a day to help soften the stool.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo specific interaction studies have been performed.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects observed during treatment in clinical studies and integrated with those collected during post-marketing experience are listed in the table below according to System Organ Class (using MedDRA terminology) and according to the following frequency: Very common ≥1\/10; Common ≥1\/100, \u003c1\/10; Uncommon ≥1\/1,000, \u003c1\/100; Rare ≥1\/10,000, \u003c1\/1,000; Very rare \u003c1\/10,000; Not known (frequency cannot be estimated from the available data). The available data are insufficient to establish the frequency of the individual effects listed.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eNot known: Cramp-like pain in the abdomen*; abdominal colic, diarrhea**, anal irritation.\u003c\/p\u003e\n\u003cp\u003e*usually isolated ** with loss of fluids and electrolytes Isolated cramping pain or abdominal colic and diarrhea are more frequent in cases of severe constipation. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at \"www.agenziafarmaco.gov.it\/it\/responsabili\".\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported. In any case, excessive doses (abuse of laxatives – frequent or prolonged use or with excessive doses) can cause abdominal pain and persistent diarrhea with consequent loss of water, mineral salts (especially potassium) and other essential nutritional factors. Fluid and electrolyte losses must be replaced. Electrolyte imbalances are characterized by the following symptoms: thirst, vomiting, weakness, edema, bone pain (osteomalacia) and hypoalbuminemia. In more serious cases, the onset of dehydration or hypokalaemia is possible which can cause cardiac or neuromuscular dysfunction, especially in the case of simultaneous treatment with cardiac glycosides, diuretics or corticosteroids. The abuse of laxatives, especially contact laxatives (stimulant laxatives), can cause dependence (and, therefore, possible need to progressively increase the dosage), chronic constipation and loss of normal intestinal functions (intestinal atony).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo adequate and well-controlled studies have been carried out on the use of the medicine during pregnancy or breastfeeding. Although there are no obvious contraindications to the use of the medicine during pregnancy and breastfeeding, it is recommended to take the medicine only if necessary and under medical supervision.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGlycerol has no influence on the ability to drive vehicles and use machines. However, it is possible that side effects may occur during treatment, therefore it is good to know the reaction to the drug before driving vehicles or using machinery.\u003c\/p\u003e","brand":"Carlo Erba","offers":[{"title":"Default Title","offer_id":46656239042887,"sku":"029651066","price":3.49,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/carlo-erba-otc-srl-glicerolo-carlo-erba-6-microclismi-soluzione-rettale-6-75g-farmacia-dottor-tili-1213792487.jpg?v=1767112571"},{"product_id":"glicerolo-afom-adulti-6-75g-soluzione-rettale-6-contenitori-monodose-con-camomilla-e-malva","title":"Glycerol Afom Adults 6.75g Rectal Solution 6 Single-Dose Containers with Chamomile and Mallow","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term treatment of occasional constipation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eGLYCEROL AFOM early childhood 2.25 g rectal solution - 6 single-dose containers with chamomile and mallow\u003c\/i\u003e. Each single-dose container contains: \u003ci\u003eactive ingredients\u003c\/i\u003e: Glycerol 2.25 g. \u003ci\u003eGLYCEROL AFOM children 4.5 g rectal solution - 6 single-dose containers with chamomile and mallow\u003c\/i\u003e. Each single-dose container contains: \u003ci\u003eactive ingredients\u003c\/i\u003e: Glycerol 4.5 g. \u003ci\u003eGLYCEROL AFOM adults 6.75 g rectal solution - 6 single-dose containers with chamomile and mallow.\u003c\/i\u003e Each single-dose container contains: \u003ci\u003eactive ingredients\u003c\/i\u003e: Glycerol 6.75 g. For the complete list of excipients see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eChamomile fluid extract, Mallow fluid extract, Potato starch, Purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hypersensitivity to the active substance or to any of the excipients, - acute abdominal pain or pain of unknown origin, - nausea or vomiting, - intestinal obstruction or stenosis, - rectal bleeding of unknown origin, - acute haemorrhoidal crisis with pain and bleeding, - severe state of dehydration.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe correct dose is the minimum sufficient to produce an easy evacuation. It is advisable to initially use the minimum doses provided. \u003cu\u003eAdults and adolescents (12-18 years)\u003c\/u\u003e: 1 single-dose adult container of 6.75 g as needed, for a maximum of 1 or 2 administrations per day. \u003cu\u003eChildren aged 6-11 years\u003c\/u\u003e: 1 single-dose container of 4.5 g for children as needed, for a maximum of 1 or 2 administrations per day. \u003cu\u003eChildren aged 2-6 years\u003c\/u\u003e: 1 single-dose infant container of 2.75 g as needed, for a maximum of 1 or 2 administrations per day. \u003cu\u003eInstructions for use\u003c\/u\u003e: Remove the cap of the single-dose container; it may be useful to lubricate the cannula with a drop of the solution itself, before introducing it into the rectum and pressing the bellows. Extract the cannula while holding down the bellows. Each container must be used for a single administration only; any residual medicine must be discarded. In children under twelve years of age the medicine can only be used after consulting a doctor. Laxatives should be used as infrequently as possible and for no longer than seven days (see section 4.4). A diet rich in liquids favors the effect of the medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore in the original packaging to protect the medicine from humidity and away from direct sources of heat.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLaxatives should be used as infrequently as possible and for no longer than seven days. Use for longer periods of time requires a doctor's prescription after adequate evaluation of the individual case. The treatment of chronic or recurrent constipation always requires the intervention of a doctor for diagnosis, prescription of drugs and monitoring during the course of therapy. It is also advisable for elderly people or those in poor health to consult their doctor before using the medicine. Abuse of laxatives can cause persistent diarrhea with consequent loss of water, mineral salts (especially potassium) and other essential nutritional factors. In more serious cases of abuse, the onset of dehydration or hypokalemia is possible, which can cause cardiac or neuromuscular dysfunction, especially in case of simultaneous treatment with cardiac glycosides, diuretics or corticosteroids. The abuse of laxatives, especially contact laxatives (stimulant laxatives), can cause dependence (and, therefore, possible need to progressively increase the dosage), chronic constipation and loss of normal intestinal functions (intestinal atony). In episodes of constipation, it is recommended first of all to correct eating habits by integrating the daily diet with an adequate intake of fiber and water. When using laxatives it is advisable to drink at least 6-8 glasses of water or other liquids a day to help soften the stool.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo specific interaction studies have been performed.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBelow are the side effects of glycerol organized according to the MedDRA system organic classification. There is insufficient data to establish the frequency of the individual effects listed. \u003ci\u003eGastrointestinal disorders\u003c\/i\u003e: Isolated crampy pain or abdominal colic and diarrhea, with loss of fluids and electrolytes, more frequent in cases of severe constipation, as well as rectal irritation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported. In any case, excessive doses (abuse of laxatives - frequent or prolonged use or with excessive doses) can cause abdominal pain, persistent diarrhea with consequent loss of water, mineral salts (especially potassium) and other essential nutritional factors. Fluid and electrolyte losses must be replaced. Electrolyte imbalances are characterized by the following symptoms: thirst, vomiting, weakness, edema, bone pain (osteomalacia) and hypoalbuminemia. In more severe cases, the onset of dehydration or hypokalemia is possible which can cause cardiac or neuromuscular dysfunction, especially in case of simultaneous treatment with cardiac glycosides, diuretics or corticosteroids. The abuse of laxatives, especially contact laxatives (stimulant laxatives), can cause dependence (and, therefore, possible need to progressively increase the dosage), chronic constipation and loss of normal intestinal functions (intestinal atony).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo adequate and well-controlled studies have been carried out on the use of the medicine during pregnancy or breastfeeding. Although there are no obvious contraindications to the use of the medicine during pregnancy and breastfeeding, it is recommended to take the medicine only if necessary and under medical supervision.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe medicine does not alter the ability to drive or use machines. However, it is possible that side effects may occur during treatment, therefore it is good to know the reaction to the drug before driving vehicles or using machinery.\u003c\/p\u003e","brand":"Aeffe Farmaceutici","offers":[{"title":"Default Title","offer_id":50753944453447,"sku":"029916083","price":2.99,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/aeffe-farmaceutici-srl-glicerolo-afom-adulti-6-75g-soluzione-rettale-6-contenitori-monodose-con-camomilla-e-malva-farmacia-dottor-tili-1213792420.jpg?v=1767131746"},{"product_id":"glicerolo-marco-viti-soluzione-rettale-adulti-6-75g-6-contenitori-monodose-con-camomilla-e-malva","title":"Glycerol Marco Viti rectal solution adults 6.75g 6 single-dose containers with chamomile and mallow","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term treatment of occasional constipation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eGLYCEROL MARCO VITI early childhood 2.25 g rectal solution\u003c\/i\u003e Each single-dose container contains: \u003ci\u003eActive ingredient\u003c\/i\u003e: Glycerol 2.25 g \u003ci\u003eGLYCEROL MARCO VITI children 4.5 g rectal solution\u003c\/i\u003e Each single-dose container contains: \u003ci\u003eActive ingredient\u003c\/i\u003e: Glycerol 4.5 g \u003ci\u003eGLYCEROL MARCO VITI adults 6.75 g rectal solution\u003c\/i\u003e Each single-dose container contains: \u003ci\u003eActive ingredient\u003c\/i\u003e: Glycerol 6.75 g For the complete list of excipients see paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eChamomile fluid extract; mauve fluid extract; pregelatinized starch; purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hypersensitivity to the active substance or to any of the excipients, - acute abdominal pain or pain of unknown origin, - nausea or vomiting, - intestinal obstruction or stenosis, - rectal bleeding of unknown origin, - acute haemorrhoidal crisis with pain and bleeding, - severe state of dehydration.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe correct dose is the minimum sufficient to produce an easy evacuation. It is advisable to initially use the minimum doses provided. \u003ci\u003eAdults and adolescents (12-18 years)\u003c\/i\u003e: 1 single-dose adult container of 6.75 g as needed, for a maximum of 1 or 2 administrations per day. \u003ci\u003eChildren aged 6-11 years\u003c\/i\u003e: 1 single-dose container of 4.5 g for children as needed, for a maximum of 1 or 2 administrations per day \u003ci\u003eChildren aged 2-6 years\u003c\/i\u003e: 1 single-dose infant container of 2.75 g as needed, for a maximum of 1 or 2 administrations per day. \u003ci\u003eInstructions for use\u003c\/i\u003e: Remove the cap. During the operation, never grasp the bellows, otherwise the medicine would leak before use. It may be useful to lubricate the cannula with a drop of the solution itself, before introducing it into the rectum and pressing the bellows. Extract the cannula while holding down the bellows. Each container must be used for a single administration only; any residual medicine must be discarded. In children under twelve years of age the medicine can only be used after consulting a doctor. Laxatives should be used as infrequently as possible and for no longer than seven days (see section 4.4). A diet rich in liquids favors the effect of the medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore in the original package in order to protect the medicine from light.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLaxatives should be used as infrequently as possible and for no longer than seven days. Use for longer periods of time requires a doctor's prescription after adequate evaluation of the individual case. The treatment of chronic or recurrent constipation always requires the intervention of a doctor for diagnosis, prescription of drugs and monitoring during the course of therapy. It is also advisable for elderly people or those in poor health to consult their doctor before using the medicine. Abuse of laxatives can cause persistent diarrhea with consequent loss of water, mineral salts (especially potassium) and other essential nutritional factors. In more serious cases of abuse, the onset of dehydration or hypokalemia is possible, which can cause cardiac or neuromuscular dysfunction, especially in case of simultaneous treatment with cardiac glycosides, diuretics or corticosteroids. The abuse of laxatives, especially contact laxatives (stimulant laxatives), can cause dependence (and, therefore, possible need to progressively increase the dosage), chronic constipation and loss of normal intestinal functions (intestinal atony). In episodes of constipation, it is recommended first of all to correct eating habits by integrating the daily diet with an adequate intake of fiber and water. When using laxatives it is advisable to drink at least 6-8 glasses of water or other liquids a day to help soften the stool.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo specific interaction studies have been performed.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBelow are the side effects of glycerol organized according to the MedDRA system organic classification. There is insufficient data to establish the frequency of the individual effects listed. \u003ci\u003eGastrointestinal disorders\u003c\/i\u003e: Isolated crampy pain or abdominal colic and diarrhea, with loss of fluids and electrolytes, more frequent in cases of severe constipation, as well as rectal irritation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported. In any case, excessive doses (abuse of laxatives - frequent or prolonged use or with excessive doses) can cause abdominal pain, persistent diarrhea with consequent loss of water, mineral salts (especially potassium) and other essential nutritional factors. Fluid and electrolyte losses must be replaced. Electrolyte imbalances are characterized by the following symptoms: thirst, vomiting, weakness, edema, bone pain (osteomalacia) and hypoalbuminemia. In more severe cases, the onset of dehydration or hypokalemia is possible which can cause cardiac or neuromuscular dysfunction, especially in case of simultaneous treatment with cardiac glycosides, diuretics or corticosteroids. The abuse of laxatives, especially contact laxatives (stimulant laxatives), can cause dependence (and, therefore, possible need to progressively increase the dosage), chronic constipation and loss of normal intestinal functions (intestinal atony).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo adequate and well-controlled studies have been carried out on the use of the medicine during pregnancy or breastfeeding. Although there are no obvious contraindications to the use of the medicine during pregnancy and breastfeeding, it is recommended to take the medicine only if necessary and under medical supervision.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe medicine does not alter the ability to drive or use machines. However, it is possible that side effects may occur during treatment, therefore it is good to know the reaction to the drug before driving vehicles or using machinery.\u003c\/p\u003e","brand":"Marco Viti","offers":[{"title":"Default Title","offer_id":51130948223303,"sku":"030334080","price":5.12,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/marco-viti-farmaceutici-spa-glicerolo-marco-viti-soluzione-rettale-adulti-6-75g-6-contenitori-monodose-con-camomilla-e-malva-farmacia-dottor-tili-1213792421.jpg?v=1767130949"},{"product_id":"clisma-fleet-21-4g-9-4g-soluzione-rettale-pronto-per-l-uso-133ml","title":"Fleet Enema 21.4g\/9.4g Rectal Solution Ready to Use 133ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term treatment of occasional constipation in adults and children over 3 years of age; pre- and post-operative intestinal emptying, in obstetrics, in preparation for radioscopic examinations and endoscopic investigations of the last intestinal tract.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach 118 ml dose contains the equivalent of 21.4 g (18.1% w\/v) sodium dihydrogen phosphate dihydrate and 9.4 g (8.0% w\/v) disodium hydrogen phosphate dodecahydrate. Contains 4.4 g of sodium per 118 ml dose delivered. Excipient with known effects: This medicinal product contains 0.0006 g\/ml benzalkonium chloride. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenzalkonium chloride Disodium edetate Distilled water q.s.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEnema Fleet is contraindicated in patients with: • Hypersensitivity to the active ingredients or to any of the excipients listed in paragraph 6.1. • Conditions causing increased absorptive capacity, decreased elimination capacity, or decreased gastric motility, for example: o   suspected intestinal obstruction o   paralytic ileus o   anorectal stenosis o   perforated anus o   congenital or acquired megacolon o   Hirschsprung's disease. • Undiagnosed gastrointestinal disorders, for example: o   symptoms suggestive of appendicitis, intestinal perforation or active inflammatory bowel disease o   undiagnosed rectal bleeding. • Congestive heart failure. • Dehydration. • Children under 3 years of age. • Clinically significant renal insufficiency. Other preparations with sodium phosphates, including oral solutions or sodium phosphate tablets, should not be administered simultaneously (see section 4.5).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e Adults and children over 12 years of age: 1 bottle (118 ml delivered dose) no more than once a day or as directed by the doctor (see section 4.4). Children aged 3 to 12 years: Half dose no more than once a day or as directed by the doctor (see sections 4.4 and 4.9). Enema Fleet is contraindicated in children under 3 years of age (see paragraph 4.3). In occasional constipation, laxatives should be used as infrequently as possible and for no more than seven days. Use for longer periods of time requires a doctor's prescription after adequate assessment of the case. Renal insufficiency: Do not administer to patients with clinically significant impairment of renal function (see section 4.3). The product should be used with caution in patients with impaired renal function, when the clinical benefit is expected to outweigh the risk of hyperphosphatemia (see section 4.4). \u003cu\u003eMethod of administration\u003c\/u\u003e For rectal use only: Lie on your left side with both knees bent, arms at rest. Remove the orange protective cap. With constant pressure, gently insert the Comfortip enema into the anus with the cannula pointing towards the navel. Press the bottle until almost all the liquid has come out. Discontinue use if resistance is encountered. Forcing the enema can cause injury. 2 to 5 minutes are enough to obtain the desired effect. For occasional constipation, rectal enemas are used to provide relief and only on a short-term basis.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store above 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not use Clisma Fleet in case of nausea, vomiting or pain. Patients should be advised to expect loose stools and should be encouraged to drink fluids to help prevent dehydration, particularly patients with conditions that may predispose to dehydration or those taking medications that may decrease the glomerular filtration rate, such as diuretics, angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin receptor blockers (sartans) or nonsteroidal anti-inflammatory drugs (NSAIDs). Since Enema Fleet contains sodium phosphates, there is a risk of elevated serum sodium and phosphate levels and decreased calcium and potassium levels and consequently hypernatremia, hyperphosphatemia, hypocalcemia and hypokalemia which may occur with clinical signs such as tetany and renal failure. Fluid and electrolyte changes are of particular concern in children with megacolon or any other condition in which there is retention of enema solution, and in patients with comorbidities. This is why Enema Fleet should be used with caution in: • elderly or weakened patients and in patients with uncontrolled arterial hypertension, ascites, heart disease, changes in the rectal mucosa (ulcers, fissures); • subjects with colostomy, patients taking diuretics or other medicines that can modify fluid and electrolyte levels; • subjects who are taking medicines known to prolong the QT interval (for example amiodarone, arsenic trioxide, astemizole, azithromycin, erythromycin, clarithromycin, chlorpromazine, cisapride, citalopram, domperidone, terfenadine, procainamide), or with known fluid and electrolyte imbalance, such as hypocalcemia, hypokalemia, hyperphosphatemia, hypernatremia. Also use with caution in patients taking medications known to affect perfusion, renal function, or hydration status. Where there is suspicion of hydroelectrolyte disorders and risk of hyperphosphatemia, hydroelectrolyte levels must be monitored before and after the administration of Fleet Enema. The product should be used with caution in patients with impaired renal function, when the clinical benefit is expected to outweigh the risk of hyperphosphatemia. Repeated and prolonged use of Clisma Fleet is not recommended as it may cause habituation. Administering more than one enema in a 24-hour period may be harmful. Enema Fleet should not be used for more than a week. Clisma Fleet must be administered according to the instructions for use (see paragraph 4.2). Patients should be advised to discontinue administration if resistance is encountered, as forcible administration of the enema may cause injury. Rectal bleeding after using Fleet Enema may indicate a serious condition. In this case the administration must be stopped immediately. In general, evacuation occurs approximately 5 minutes after administration of Fleet Enema, therefore, retention times of more than 5 minutes are not recommended. If evacuation does not occur after using Clisma Fleet or if the retention time lasts more than 10 minutes, serious side effects may occur. No other administrations must be used and the patient's condition must be evaluated in order to identify any hydroelectrolyte alterations and to minimize the risk of severe hyperphosphatemia (see sections 4.8 and 4.9). \u003ci\u003eImportant information about some excipients\u003c\/i\u003e Due to the presence of benzalkonium chloride, the product is irritating and can cause local skin reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUse with caution in patients who are receiving calcium channel blockers, diuretics, lithium or other medicinal products that may affect fluid and electrolyte levels as hyperphosphataemia, hypocalcaemia, hypokalaemia, acidosis and hypernatremic dehydration may occur (see section 4.4). Other preparations with sodium phosphates including oral solutions or sodium phosphate tablets should not be administered simultaneously (see section 4.3). Since hypernatremia is associated with low lithium levels, concomitant use of Fleet Enema and lithium may cause a reduction in serum lithium levels with decreased efficacy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEnema Fleet is well tolerated if used as indicated. However, adverse events associated with the use of Enema Fleet have frequently been reported. In some cases, adverse events may occur, especially if the enema is used inappropriately. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Undesirable effects are listed below, by MedDRA system organ class and using the following frequency: very common (≥ 1\/10), common (≥ 1\/100, \u003c1\/10), uncommon (≥ 1\/1,000, \u003c1\/100), rare (≥ 1\/10,000, \u003c1\/1,000), very rare (\u003c1\/10,000), not known (frequency cannot be estimated from the available data): \u003cu\u003eImmune system disorders\u003c\/u\u003e: Very rare: hypersensitivity e.g. urticaria. \u003cu\u003ePathologies of the skin and subcutaneous tissue\u003c\/u\u003e: Very rare: blisters, itching, burning. \u003cu\u003eMetabolism and nutrition disorders\u003c\/u\u003e: Very rare: dehydration, hyperphosphatemia, hypocalcaemia, hypokalaemia, hypernatraemia, metabolic acidosis. \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e: Very rare: nausea, vomiting, abdominal pain, abdominal distension, diarrhoea, gastrointestinal pain, anal discomfort and proctalgia. \u003cu\u003eSystemic pathologies and conditions relating to the administration site\u003c\/u\u003e: Very rare: rectal irritation, pain, burning, chills. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFatal cases have been reported after administration of excessive doses, after retention, in case of administration to pediatric patients or in obstructed patients. In case of overdose or retention, hyperphosphatemia, hypocalcemia, hypernatremia, hyperphosphatemia, hypernatremic dehydration, hypokalaemia, hypovolemia, acidosis and tetany may occur. Recovery from toxic effects can normally be achieved by rehydration. Treatment of electrolyte imbalances may require immediate medical intervention through the administration of adequate electrolytes and fluid therapy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince there are no relevant data available to evaluate the potential for fetal malformation or other foetotoxic effects when administered during pregnancy, Fleet Enema should be used under direct medical supervision only at the time of delivery or postpartum. Because sodium phosphate may pass into breast milk, it is recommended that breast milk be expressed and discarded for at least 24 hours after administering Fleet Enema.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eClisma Fleet does not affect the ability to drive and use machinery, but it is necessary to remain near toilets after using this medicine.\u003c\/p\u003e","brand":"Casen Recordati","offers":[{"title":"Default Title","offer_id":51131195883847,"sku":"029319011","price":5.58,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/casen-recordati-sl-clisma-fleet-21-4g-9-4g-soluzione-rettale-pronto-per-l-uso-133ml-farmacia-dottor-tili-1213792402.jpg?v=1767132647"},{"product_id":"dulcolax-5mg-40-compresse-rivestite","title":"Dulcolax 5mg 40 coated tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term treatment of occasional constipation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCOATED TABLETS One coated tablet contains: bisacodyl 5 mg. Excipients with known effects: lactose, sucrose, castor oil. ADULTS SUPPOSITORIES One suppository contains: bisacodyl 10 mg. CHILDREN SUPPOSITORIES One suppository contains: bisacodyl 5 mg. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCOATED TABLETS \u003cb\u003eLactose\u003c\/b\u003e \u003cb\u003emonohydrate\u003c\/b\u003e, corn starch, modified starch, glycerol, magnesium stearate, \u003cb\u003esucrose\u003c\/b\u003e, talc, gum arabic, titanium dioxide (E171), methacrylic acid\/methyl methacrylate copolymer (1:1), methacrylic acid\/methyl methacrylate copolymer (1:2), \u003cb\u003ecastor oil\u003c\/b\u003e, macrogol 6000, iron oxide (E172), white wax, carnauba wax, shellac. SUPPOSITORIES Triglycerides of saturated fatty acids.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients. Dulcolax is also contraindicated in patients with paralytic ileus, acute abdominal conditions, such as appendicitis, and severe abdominal pain associated with nausea and vomiting which may be indicative signs of serious pathological conditions, intestinal obstruction or stenosis, acute inflammation of the gastrointestinal tract, rectal bleeding of unknown origin, severe state of dehydration. Pregnancy and breastfeeding (see section 4.6). The use of Dulcolax is contraindicated in cases of rare hereditary conditions that may be incompatible with the intake of one of the excipients (see section 4.4 \"special warnings and precautions for use\"). Dulcolax is contraindicated in children under 2 years of age. Suppositories are contraindicated in cases of anal fissures and ulcers (perianal pain and bleeding may occur).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCOATED TABLETS - Adults: 1-2 coated tablets per day. \u003cu\u003ePediatric population\u003c\/u\u003e \u003ci\u003e - \u003c\/i\u003eChildren over 10 years: 1-2 coated tablets per day. - Children aged between 2 and 10 years: 1 coated tablet per day. It is advisable to start with the minimum expected dose. The dose can then be increased, up to the maximum recommended dose, for regular stool evacuation. The maximum daily dose must never be exceeded. \u003cu\u003eInstructions for use\u003c\/u\u003e Take the coated tablets preferably in the evening to determine an evacuation the following morning (after approximately 10 hours). When administered in the morning, on an empty stomach, the effect is obtained after approximately five hours. The coated tablets should not be administered together with products that reduce the acidity of the upper gastrointestinal tract, such as milk, antacids (e.g. bicarbonate) or proton pump inhibitors. The coated tablets should be swallowed whole. Swallow together with an adequate quantity of water (a large glass). A diet rich in liquids favors the effect of the medicine. SUPPOSITORIES - Adults: 1 adult suppository (10 mg) per day. \u003cu\u003ePediatric population\u003c\/u\u003e - Children over 10 years: 1 adult suppository (10 mg) per day. - Children aged between 2 and 10 years: 1 children's suppository (5 mg) per day. The maximum daily dose must never be exceeded. Children aged 10 years and younger with chronic or persistent constipation should take Dulcolax under their doctor's supervision. Dulcolax must not be administered to children under two years of age. \u003cu\u003eInstructions for use\u003c\/u\u003e The effect of suppositories usually occurs in about 20 minutes (range: 10 - 30 minutes). Do not exceed the recommended doses. Laxatives should be used as infrequently as possible and for no longer than seven days. Use for longer periods of time requires a doctor's prescription after adequate evaluation of the individual case.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCoated tablets: this medicine does not require any special storage conditions. Suppositories: Do not store above 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eWarnings\u003c\/u\u003e Like all laxatives, Dulcolax should not be taken continuously every day or for long periods of time without investigating the cause of the constipation. In case of diabetes mellitus, hypertension or heart disease, use only after consulting your doctor. Abuse of laxatives (frequent or prolonged use or with excessive doses) can cause persistent diarrhea with consequent loss of water, mineral salts (especially potassium) and other essential nutritional factors. In more severe cases, the onset of dehydration or hypokalemia is possible which can cause cardiac or neuromuscular dysfunction, especially in case of simultaneous treatment with cardiac glycosides, diuretics or corticosteroids. Intestinal loss of fluids can cause dehydration. Symptoms may be thirst and oliguria. In patients for whom dehydration may be dangerous (patients with renal insufficiency, elderly patients), treatment with Dulcolax should be stopped and restarted only under medical supervision. Hematochezia (blood in the stool) may occur in patients, which is usually mild and goes away on its own. The abuse of laxatives, especially contact laxatives (stimulant laxatives), can cause dependence (and, therefore, possible need to progressively increase the dosage), chronic constipation and loss of normal intestinal functions (intestinal atony). Cases of dizziness and\/or syncope have been reported after taking Dulcolax. The data relating to these cases suggest that the events, rather than a phenomenon related to the intake of Dulcolax, could be interpreted as a manifestation of \"defecation syncope\" (attributable to the effort of the act of defecation), or as a vasovagal response to abdominal pain related to the constipation itself. The use of suppositories can lead to painful sensations and local irritation, in particular, in patients with fissures and ulcerative proctitis (see section 4.3 “contraindications”). Stimulant laxatives including Dulcolax do not contribute to weight loss (see section 5.1 “Pharmacodynamic properties”). \u003cb\u003eImportant information about some excipients:\u003c\/b\u003e Dulcolax tablets contain 33.2 mg of \u003cu\u003elactose\u003c\/u\u003e equal to 66.42 mg in case of taking the maximum daily dose, for the treatment of constipation in adults and adolescents over 10 years of age. Patients suffering from rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine tablets. Dulcolax tablets contain 23.4 mg of \u003cu\u003esucrose\u003c\/u\u003e equal to 46.8 mg when taking the maximum daily dose for the treatment of constipation in adults and adolescents over 10 years of age. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase deficiency should not take this medicine tablets. Dulcolax tablets may cause gastric upset and diarrhoea. \u003cu\u003ePrecautions for use\u003c\/u\u003e In children aged between 2 years and 10 years the medicine can only be used after consulting the doctor (see section 4.3). Like all laxatives, it should not be taken daily or for prolonged periods without first evaluating the cause of the constipation. The treatment of chronic or recurrent constipation always requires the intervention of a doctor for diagnosis, prescription of drugs and monitoring during the course of therapy. Consult your doctor when the need for the laxative derives from a sudden change in previous intestinal habits (frequency and characteristics of evacuations) that lasts for more than two weeks or when the use of the laxative fails to produce effects. It is also advisable for elderly people or those in poor health to consult their doctor before using the medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eConcomitant administration of diuretics or adrenocorticosteroids and excessive doses of Dulcolax may lead to an increased risk of electrolyte imbalance. This imbalance, in turn, can lead to increased sensitivity to cardiac glycosides. Laxatives can reduce the residence time in the intestine, and therefore the absorption, of other drugs administered simultaneously orally. Therefore, avoid ingesting laxatives and other drugs at the same time: after taking a medicine, leave an interval of at least two hours before taking the laxative. Milk or antacids can change the effect of the medicine; leave an interval of at least one hour before taking the laxative. Concomitant use of other laxatives may potentiate the gastrointestinal side effects of Dulcolax.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe most commonly reported side effects during treatment with Dulcolax are abdominal pain and diarrhea. \u003cu\u003eImmune system disorders\u003c\/u\u003e: anaphylactic reactions, angioneurotic edema as well as other hypersensitivity reactions. \u003cu\u003eMetabolism and nutrition disorders\u003c\/u\u003e: dehydration. \u003cu\u003eNervous system disorders\u003c\/u\u003e: dizziness, syncope. The phenomena of dizziness and syncope that occur after taking bisacodyl appear to be attributable to a vasovagal response (resulting, for example, from abdominal pain, or the evacuation of feces). \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e: abdominal cramps, abdominal pain, diarrhea, nausea, hematochezia (blood in stool), vomiting, abdominal discomfort, anorectal discomfort, colitis including ischemic colitis. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e \u003cu\u003eReporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: \u003c\/u\u003e \u003cu\u003ehttp:\/\/www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetta-reazione-avversa.\u003c\/u\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSymptoms\u003c\/u\u003e Excessive doses can cause abdominal pain and diarrhea, and significant losses of potassium and other electrolytes. Chronic overdose of Dulcolax, as with other laxatives, can cause chronic diarrhea, abdominal pain, hypokalemia, secondary hyperaldosteronism and kidney stones. Renal tubular injury, metabolic alkalosis, and muscle weakness secondary to hypokalemia have also been described in association with chronic laxative abuse. Also see what is reported in the paragraph “Special warnings and precautions for use” regarding the abuse of laxatives. \u003cu\u003eTreatment\u003c\/u\u003e If action is taken within a short time of ingesting the oral form of Dulcolax, absorption can be reduced or avoided by inducing vomiting or gastric lavage. Fluid and electrolyte losses must be replaced. This is especially important in elderly and young patients. The administration of spasmolytics may be useful.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e There are no adequate and well-controlled studies on the use of the medicine during pregnancy. Therefore, although unwanted or toxic effects have never been reported during pregnancy, like all medicines, Dulcolax must be used only if necessary, under the direct supervision of a doctor, after evaluating the expected benefit for the mother in relation to the possible risk for the fetus. \u003cu\u003eFertility\u003c\/u\u003e No studies have been conducted to investigate the effects on human fertility. \u003cu\u003eBreastfeeding\u003c\/u\u003e Clinical data demonstrate that neither the active form of bisacodyl BHPM, bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), nor its glucuronic derivatives are excreted in breast milk, however the medicine should only be used if necessary, under direct medical supervision, after evaluating the expected benefit for the mother in relation to the possible risk for the infant.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo studies on the effects on the ability to drive and use machines have been performed. However, patients should be informed that due to vasovagal response (e.g., abdominal spasm), dizziness and\/or syncope may occur. If patients experience abdominal spasm they should avoid potentially dangerous activities such as driving or using machinery.\u003c\/p\u003e","brand":"Opella Healthcare","offers":[{"title":"Default Title","offer_id":51131201257799,"sku":"008997064","price":12.93,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/opella-healthcare-dulcolax-5mg-40-compresse-rivestite-farmacia-dottor-tili-1258975859.jpg?v=1789561897"},{"product_id":"clisma-fleet-21-4g-9-4g-soluzione-rettale-pronto-per-l-uso-4-flaconi-133ml","title":"Fleet Enema 21.4g\/9.4g Rectal Solution Ready to Use 4 Bottles 133ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term treatment of occasional constipation in adults and children over 3 years of age; pre- and post-operative intestinal emptying, in obstetrics, in preparation for radioscopic examinations and endoscopic investigations of the last intestinal tract.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach 118 ml dose contains the equivalent of 21.4 g (18.1% w\/v) sodium dihydrogen phosphate dihydrate and 9.4 g (8.0% w\/v) disodium hydrogen phosphate dodecahydrate. Contains 4.4 g of sodium per 118 ml dose delivered. Excipient with known effects: This medicinal product contains 0.0006 g\/ml benzalkonium chloride. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenzalkonium chloride Disodium edetate Distilled water q.s.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEnema Fleet is contraindicated in patients with: • Hypersensitivity to the active ingredients or to any of the excipients listed in paragraph 6.1. • Conditions causing increased absorptive capacity, decreased elimination capacity, or decreased gastric motility, for example: o   suspected intestinal obstruction o   paralytic ileus o   anorectal stenosis o   perforated anus o   congenital or acquired megacolon o   Hirschsprung's disease. • Undiagnosed gastrointestinal disorders, for example: o   symptoms suggestive of appendicitis, intestinal perforation or active inflammatory bowel disease o   undiagnosed rectal bleeding. • Congestive heart failure. • Dehydration. • Children under 3 years of age. • Clinically significant renal insufficiency. Other preparations with sodium phosphates, including oral solutions or sodium phosphate tablets, should not be administered simultaneously (see section 4.5).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e Adults and children over 12 years of age: 1 bottle (118 ml delivered dose) no more than once a day or as directed by the doctor (see section 4.4). Children aged 3 to 12 years: Half dose no more than once a day or as directed by the doctor (see sections 4.4 and 4.9). Enema Fleet is contraindicated in children under 3 years of age (see paragraph 4.3). In occasional constipation, laxatives should be used as infrequently as possible and for no more than seven days. Use for longer periods of time requires a doctor's prescription after adequate evaluation of the case. Renal insufficiency: Do not administer to patients with clinically significant impairment of renal function (see section 4.3). The product should be used with caution in patients with impaired renal function, when the clinical benefit is expected to outweigh the risk of hyperphosphatemia (see section 4.4). \u003cu\u003eMethod of administration\u003c\/u\u003e For rectal use only: Lie on your left side with both knees bent, arms at rest. Remove the orange protective cap. With constant pressure, gently insert the Comfortip enema into the anus with the cannula pointing towards the navel. Press the bottle until almost all the liquid has come out. Discontinue use if resistance is encountered. Forcing the enema can cause injury. 2 to 5 minutes are enough to obtain the desired effect. For occasional constipation, rectal enemas are used to provide relief and only on a short-term basis.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store above 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not use Clisma Fleet in case of nausea, vomiting or pain. Patients should be advised to expect loose stools and should be encouraged to drink fluids to help prevent dehydration, particularly patients with conditions that may predispose to dehydration or those taking medications that may decrease the glomerular filtration rate, such as diuretics, angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin receptor blockers (sartans) or nonsteroidal anti-inflammatory drugs (NSAIDs). Since Enema Fleet contains sodium phosphates, there is a risk of elevated serum sodium and phosphate levels and decreased calcium and potassium levels and consequently hypernatremia, hyperphosphatemia, hypocalcemia and hypokalemia which may occur with clinical signs such as tetany and renal failure. Fluid and electrolyte changes are of particular concern in children with megacolon or any other condition in which there is retention of enema solution, and in patients with comorbidities. This is why Enema Fleet should be used with caution in: • elderly or weakened patients and in patients with uncontrolled arterial hypertension, ascites, heart disease, changes in the rectal mucosa (ulcers, fissures); • subjects with colostomy, patients taking diuretics or other medicines that can modify fluid and electrolyte levels; • subjects who are taking medicines known to prolong the QT interval (for example amiodarone, arsenic trioxide, astemizole, azithromycin, erythromycin, clarithromycin, chlorpromazine, cisapride, citalopram, domperidone, terfenadine, procainamide), or with known fluid and electrolyte imbalance, such as hypocalcemia, hypokalemia, hyperphosphatemia, hypernatremia. Also use with caution in patients taking medications known to affect perfusion, renal function, or hydration status. Where there is suspicion of hydroelectrolyte disorders and risk of hyperphosphatemia, hydroelectrolyte levels must be monitored before and after the administration of Fleet Enema. The product should be used with caution in patients with impaired renal function, when the clinical benefit is expected to outweigh the risk of hyperphosphatemia. Repeated and prolonged use of Clisma Fleet is not recommended as it may cause habituation. Administering more than one enema in a 24-hour period may be harmful. Enema Fleet should not be used for more than a week. Clisma Fleet must be administered according to the instructions for use (see paragraph 4.2). Patients should be advised to discontinue administration if resistance is encountered, as forcible administration of the enema may cause injury. Rectal bleeding after using Fleet Enema may indicate a serious condition. In this case the administration must be stopped immediately. In general, evacuation occurs approximately 5 minutes after administration of Fleet Enema, therefore, retention times of more than 5 minutes are not recommended. If evacuation does not occur after using Clisma Fleet or if the retention time lasts more than 10 minutes, serious side effects may occur. No other administrations must be used and the patient's condition must be evaluated in order to identify any hydroelectrolyte alterations and to minimize the risk of severe hyperphosphatemia (see sections 4.8 and 4.9). \u003ci\u003eImportant information about some excipients\u003c\/i\u003e Due to the presence of benzalkonium chloride, the product is irritating and can cause local skin reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUse with caution in patients who are receiving calcium channel blockers, diuretics, lithium or other medicinal products that may affect fluid and electrolyte levels as hyperphosphataemia, hypocalcaemia, hypokalaemia, acidosis and hypernatremic dehydration may occur (see section 4.4). Other preparations with sodium phosphates including oral solutions or sodium phosphate tablets should not be administered simultaneously (see section 4.3). Since hypernatremia is associated with low lithium levels, concomitant use of Fleet Enema and lithium may cause a reduction in serum lithium levels with decreased efficacy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEnema Fleet is well tolerated if used as indicated. However, adverse events associated with the use of Enema Fleet have frequently been reported. In some cases, adverse events may occur, especially if the enema is used inappropriately. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Undesirable effects are listed below, by MedDRA system organ class and using the following frequency: very common (≥ 1\/10), common (≥ 1\/100, \u003c1\/10), uncommon (≥ 1\/1,000, \u003c1\/100), rare (≥ 1\/10,000, \u003c1\/1,000), very rare (\u003c1\/10,000), not known (frequency cannot be estimated from the available data): \u003cu\u003eImmune system disorders\u003c\/u\u003e: Very rare: hypersensitivity e.g. urticaria. \u003cu\u003ePathologies of the skin and subcutaneous tissue\u003c\/u\u003e: Very rare: blisters, itching, burning. \u003cu\u003eMetabolism and nutrition disorders\u003c\/u\u003e: Very rare: dehydration, hyperphosphatemia, hypocalcaemia, hypokalaemia, hypernatraemia, metabolic acidosis. \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e: Very rare: nausea, vomiting, abdominal pain, abdominal distension, diarrhoea, gastrointestinal pain, anal discomfort and proctalgia. \u003cu\u003eSystemic pathologies and conditions relating to the administration site\u003c\/u\u003e: Very rare: rectal irritation, pain, burning, chills. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFatal cases have been reported after administration of excessive doses, after retention, in case of administration to pediatric patients or in obstructed patients. In case of overdose or retention, hyperphosphatemia, hypocalcemia, hypernatremia, hyperphosphatemia, hypernatremic dehydration, hypokalaemia, hypovolemia, acidosis and tetany may occur. Recovery from toxic effects can normally be achieved by rehydration. Treatment of electrolyte imbalances may require immediate medical intervention through the administration of adequate electrolytes and fluid therapy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince there are no relevant data available to evaluate the potential for fetal malformation or other foetotoxic effects when administered during pregnancy, Fleet Enema should be used under direct medical supervision only at the time of delivery or postpartum. Because sodium phosphate may pass into breast milk, it is recommended that breast milk be expressed and discarded for at least 24 hours after administering Fleet Enema.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eClisma Fleet does not affect the ability to drive and use machinery, but it is necessary to remain near toilets after using this medicine.\u003c\/p\u003e","brand":"Casen Recordati","offers":[{"title":"Default Title","offer_id":51131262697799,"sku":"029319023","price":16.46,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/casen-recordati-sl-clisma-fleet-21-4g-9-4g-soluzione-rettale-pronto-per-l-uso-4-flaconi-133ml-farmacia-dottor-tili-1213792287.jpg?v=1767144047"},{"product_id":"clisma-lax-soluzione-rettale-133ml","title":"Clisma Lax rectal solution 133ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term treatment of occasional constipation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 ml contain 13.91 g of anhydrous monobasic sodium phosphate (NaH\u003csub\u003e2\u003c\/sub\u003ePO\u003csub\u003e4\u003c\/sub\u003e); 3.18 g of dibasic sodium phosphate (Na\u003csub\u003e2\u003c\/sub\u003eHPO\u003csub\u003e4\u003c\/sub\u003e). Excipients with known effects: sodium benzoate (100mg per 100ml) and methylparahydroxybenzoate (50mg per 100ml). For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSodium hydroxide, sodium benzoate, methyl parahydroxybenzoate, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e-Hypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. - acute abdominal pain or of unknown origin - nausea or vomiting - intestinal obstruction or stenosis or anorectal stenosis - intestinal sub-occlusion - mechanical ileus - paralytic ileus - inflammatory intestinal disorders and other conditions that can increase the absorption of the medicine - anal perforation - congenital or acquired megacolon - Hirschsprung's disease - rectal bleeding of unknown origin - acute haemorrhoidal crisis with pain and bleeding - severe state of dehydration - children under the age of twelve. Phosphates are contraindicated in patients with cardiac disorders, severe renal insufficiency or in the presence of hyperphosphatemia. Other preparations with sodium phosphates, including oral solutions or sodium phosphate tablets, should not be administered simultaneously (see section 4.5).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e Adults and adolescents (12-18 years): the entire dose of the bottle. \u003cu\u003eMethod of administration\u003c\/u\u003e Do not exceed the recommended doses. Laxatives should be used as infrequently as possible and for no longer than seven days. Use for longer periods of time requires a doctor's prescription after adequate evaluation of the individual case. Take preferably in the evening.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePediatric population\u003c\/u\u003e: The 133 ml bottle should not be used in children under 12 years of age. Abuse of laxatives (frequent or prolonged use or with excessive doses) can cause persistent diarrhea with consequent loss of water, mineral salts (especially potassium) and other essential nutritional factors. In more severe cases, the onset of dehydration or hypokalemia is possible which can cause cardiac or neuromuscular dysfunction, especially in case of simultaneous treatment with cardiac glycosides, diuretics or corticosteroids. Patients should be encouraged to drink fluids to help prevent dehydration, particularly patients with conditions that may predispose to dehydration, or those taking medications that may decrease the glomerular filtration rate, such as diuretics, angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin receptor blockers (sartans), or nonsteroidal anti-inflammatory drugs (NSAIDs). Since Clisma lax contains sodium phosphates, there is a risk of elevated serum sodium and phosphate levels and decreased calcium and potassium levels, and consequently hypernatraemia, hyperphosphataemia, hypocalcaemia and hypokalaemia, which may occur with clinical signs such as tetany and renal failure. Abuse of laxatives can cause dependence (and, therefore, possible need to progressively increase the dosage), chronic constipation and loss of normal intestinal functions (intestinal atony). Repeated use of laxatives can give rise to addiction or various types of damage. Prolonged use of a laxative to treat constipation is not recommended. The pharmacological treatment of constipation must be considered an adjuvant to the hygienic-dietary treatment (e.g. increase in vegetable fibers and liquids in the diet, physical activity and re-education of intestinal motility). The treatment of chronic or recurrent constipation always requires the intervention of a doctor for diagnosis, prescription of drugs and monitoring during the course of therapy. A careful evaluation by the doctor is essential when the need for the laxative derives from a sudden change in previous intestinal habits (frequency and characteristics of evacuations) that lasts for more than two weeks or when the use of the laxative fails to produce effects. Elderly people or those in poor health and patients with uncontrolled arterial hypertension, ascites, heart disease, changes in the rectal mucosa (ulcers, fissures) should consult their doctor before using the medicine. Patients should be advised to discontinue administration if resistance is encountered, as forcible administration of the enema may cause injury. In episodes of constipation, it is recommended first of all to correct eating habits by integrating the daily diet with an adequate intake of fiber and water. When using laxatives it is advisable to drink at least 6-8 glasses of water or other liquids a day to help soften the stool.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe systemic absorption of sodium phosphate rectal solution is limited, however in some conditions it may be increased and predispose to possible interactions with other drugs. The simultaneous intake of drugs that can have effects on electrolyte balance (such as diuretics, cortisone, calcium channel blockers, lithium) can facilitate the onset of hyperphosphatemia, hypercalcemia and hypernatremia. Patients taking drugs that can prolong the QT interval may be at greater risk of developing this adverse reaction if treated concomitantly with sodium phosphate. Since hypernatremia is associated with low lithium levels, the concomitant use of Enema lax and lithium may cause a reduction in serum lithium levels, with a decrease in efficacy. Concomitant use of calcium supplements or calcium-containing antacids may increase the risk of ectopic calcification. Other preparations with sodium phosphates, including oral solutions or sodium phosphate tablets, should not be administered simultaneously (see section 4.3).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBelow are the side effects of sodium phosphate organized according to the MedDRA system organic classification. There is insufficient data to establish the frequency of the individual effects listed. \u003ci\u003eImmune system disorders\u003c\/i\u003e Hypersensitivity reactions (e.g. urticaria) \u003ci\u003ePathologies of the skin and subcutaneous tissue\u003c\/i\u003e Blisters, itching, burning \u003ci\u003eGastrointestinal disorders\u003c\/i\u003e Isolated crampy pain or abdominal colic and diarrhea, with loss of fluids and electrolytes, more frequent in cases of severe constipation, as well as rectal irritation. Nausea, vomiting. \u003ci\u003eMetabolism and nutrition disorders\u003c\/i\u003e Hyperphosphatemia, hypokalemia, hypernatremia, hypocalcemia, and tissue calcification may rarely occur. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe effect most frequently observed following ingestion or rectal administration is gastrointestinal irritation (abdominal pain, nausea, vomiting, diarrhoea). Persistent diarrhea results in loss of water, mineral salts (especially potassium) and other essential nutritional factors. Fluid and electrolyte losses must be replaced. Electrolyte imbalances are characterized by the following symptoms: thirst, vomiting, weakness, edema, bone pain (osteomalacia) and hypoalbuminemia. In more severe cases, the onset of dehydration or hypokalemia is possible which can cause cardiac or neuromuscular dysfunction, especially in the case of simultaneous treatment with cardiac glycosides, diuretics or corticosteroids. Fluid and electrolyte losses must be replaced. Generally, conservative measures are sufficient; plenty of liquids must be given, especially fruit juices. See also what is reported in paragraph 4.4 regarding the abuse of laxatives. If a significant amount of phosphate is absorbed, hyperphosphatemia, hypocalcemia, and hypomagnesemia may occur. Alterations in fluid and electrolyte balance have been observed following oral, rectal and intravenous exposure. Severe hyperphosphatemia and hypocalcemia may cause tetany, convulsions, bradycardia, QT interval prolongation, arrhythmia, coma and cardiac arrest. Severe dehydration, hypernatremia, hypotension, metabolic acidosis, and tachycardia may also occur. The elderly, children and patients with renal insufficiency are at increased risk of toxic effects.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no adequate and well-controlled studies on the use of the medicine during pregnancy or breastfeeding. Therefore the medicine must be used only if necessary, under the direct supervision of the doctor, after having evaluated the expected benefit for the mother in relation to the possible risk for the fetus or infant.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe medicine does not alter the ability to drive or use machines. However, it is possible that side effects may occur during treatment, therefore it is good to know the reaction to the drug before driving vehicles or using machinery.\u003c\/p\u003e","brand":"Alfasigma","offers":[{"title":"Default Title","offer_id":51131295793479,"sku":"024995033","price":5.77,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/alfasigma-spa-clisma-lax-soluzione-rettale-133ml-farmacia-dottor-tili-1213792210.jpg?v=1767134489"},{"product_id":"dulcolax-adulti-10mg-6-supposte","title":"Dulcolax adults 10mg 6 suppositories","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term treatment of occasional constipation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCOATED TABLETS One coated tablet contains: bisacodyl 5 mg. Excipients with known effects: lactose, sucrose, castor oil. ADULTS SUPPOSITORIES One suppository contains: bisacodyl 10 mg. CHILDREN SUPPOSITORIES One suppository contains: bisacodyl 5 mg. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCOATED TABLETS \u003cb\u003eLactose\u003c\/b\u003e \u003cb\u003emonohydrate\u003c\/b\u003e, corn starch, modified starch, glycerol, magnesium stearate, \u003cb\u003esucrose\u003c\/b\u003e, talc, gum arabic, titanium dioxide (E171), methacrylic acid\/methyl methacrylate copolymer (1:1), methacrylic acid\/methyl methacrylate copolymer (1:2), \u003cb\u003ecastor oil\u003c\/b\u003e, macrogol 6000, iron oxide (E172), white wax, carnauba wax, shellac. SUPPOSITORIES Triglycerides of saturated fatty acids.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients. Dulcolax is also contraindicated in patients with paralytic ileus, acute abdominal conditions, such as appendicitis, and severe abdominal pain associated with nausea and vomiting which may be signs indicative of serious pathological conditions, in intestinal obstruction or stenosis, acute inflammation of the gastrointestinal tract, rectal bleeding of unknown origin, severe state of dehydration. Pregnancy and breastfeeding (see section 4.6). The use of Dulcolax is contraindicated in cases of rare hereditary conditions that may be incompatible with the intake of one of the excipients (see section 4.4 \"special warnings and precautions for use\"). Dulcolax is contraindicated in children under 2 years of age. Suppositories are contraindicated in cases of anal fissures and ulcers (perianal pain and bleeding may occur).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCOATED TABLETS - Adults: 1-2 coated tablets per day. \u003cu\u003ePediatric population\u003c\/u\u003e \u003ci\u003e - \u003c\/i\u003eChildren over 10 years: 1-2 coated tablets per day. - Children aged between 2 and 10 years: 1 coated tablet per day. It is advisable to start with the minimum expected dose. The dose can then be increased, up to the maximum recommended dose, for regular stool evacuation. The maximum daily dose must never be exceeded. \u003cu\u003eInstructions for use\u003c\/u\u003e Take the coated tablets preferably in the evening to determine an evacuation the following morning (after approximately 10 hours). When administered in the morning, on an empty stomach, the effect is obtained after approximately five hours. The coated tablets should not be administered together with products that reduce the acidity of the upper gastrointestinal tract, such as milk, antacids (e.g. bicarbonate) or proton pump inhibitors. The coated tablets should be swallowed whole. Swallow together with an adequate quantity of water (a large glass). A diet rich in liquids favors the effect of the medicine. SUPPOSITORIES - Adults: 1 adult suppository (10 mg) per day. \u003cu\u003ePediatric population\u003c\/u\u003e - Children over 10 years: 1 adult suppository (10 mg) per day. - Children aged between 2 and 10 years: 1 children's suppository (5 mg) per day. The maximum daily dose must never be exceeded. Children aged 10 years and younger with chronic or persistent constipation should take Dulcolax under their doctor's supervision. Dulcolax must not be administered to children under two years of age. \u003cu\u003eInstructions for use\u003c\/u\u003e The effect of suppositories usually occurs in about 20 minutes (range: 10 - 30 minutes). Do not exceed the recommended doses. Laxatives should be used as infrequently as possible and for no longer than seven days. Use for longer periods of time requires a doctor's prescription after adequate evaluation of the individual case.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCoated tablets: this medicine does not require any special storage conditions. Suppositories: Do not store above 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eWarnings\u003c\/u\u003e Like all laxatives, Dulcolax should not be taken continuously every day or for long periods of time without investigating the cause of the constipation. In case of diabetes mellitus, hypertension or heart disease, use only after consulting your doctor. Abuse of laxatives (frequent or prolonged use or with excessive doses) can cause persistent diarrhea with consequent loss of water, mineral salts (especially potassium) and other essential nutritional factors. In more severe cases, the onset of dehydration or hypokalemia is possible which can cause cardiac or neuromuscular dysfunction, especially in case of simultaneous treatment with cardiac glycosides, diuretics or corticosteroids. Intestinal loss of fluids can cause dehydration. Symptoms may be thirst and oliguria. In patients for whom dehydration may be dangerous (patients with renal insufficiency, elderly patients), treatment with Dulcolax should be stopped and restarted only under medical supervision. Hematochezia (blood in the stool) may occur in patients, which is usually mild and goes away on its own. The abuse of laxatives, especially contact laxatives (stimulant laxatives), can cause dependence (and, therefore, possible need to progressively increase the dosage), chronic constipation and loss of normal intestinal functions (intestinal atony). Cases of dizziness and\/or syncope have been reported after taking Dulcolax. The data relating to these cases suggest that the events, rather than a phenomenon related to the intake of Dulcolax, could be interpreted as a manifestation of \"defecation syncope\" (attributable to the effort of the act of defecation), or as a vasovagal response to abdominal pain related to the constipation itself. The use of suppositories can lead to painful sensations and local irritation, in particular, in patients with fissures and ulcerative proctitis (see section 4.3 “contraindications”). Stimulant laxatives including Dulcolax do not contribute to weight loss (see section 5.1 “Pharmacodynamic properties”). \u003cb\u003eImportant information about some excipients:\u003c\/b\u003e Dulcolax tablets contain 33.2 mg of \u003cu\u003elactose\u003c\/u\u003e equal to 66.42 mg in case of taking the maximum daily dose, for the treatment of constipation in adults and adolescents over 10 years of age. Patients suffering from rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine tablets. Dulcolax tablets contain 23.4 mg of \u003cu\u003esucrose\u003c\/u\u003e equal to 46.8 mg when taking the maximum daily dose for the treatment of constipation in adults and adolescents over 10 years of age. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase deficiency should not take this medicine tablets. Dulcolax tablets may cause gastric upset and diarrhoea. \u003cu\u003ePrecautions for use\u003c\/u\u003e In children aged between 2 years and 10 years the medicine can only be used after consulting the doctor (see section 4.3). Like all laxatives, it should not be taken daily or for prolonged periods without first evaluating the cause of the constipation. The treatment of chronic or recurrent constipation always requires the intervention of a doctor for diagnosis, prescription of drugs and monitoring during the course of therapy. Consult your doctor when the need for the laxative derives from a sudden change in previous intestinal habits (frequency and characteristics of evacuations) that lasts for more than two weeks or when the use of the laxative fails to produce effects. It is also advisable for elderly people or those in poor health to consult their doctor before using the medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eConcomitant administration of diuretics or adrenocorticosteroids and excessive doses of Dulcolax may lead to an increased risk of electrolyte imbalance. This imbalance, in turn, can lead to increased sensitivity to cardiac glycosides. Laxatives can reduce the residence time in the intestine, and therefore the absorption, of other drugs administered simultaneously orally. Therefore, avoid ingesting laxatives and other drugs at the same time: after taking a medicine, leave an interval of at least two hours before taking the laxative. Milk or antacids can change the effect of the medicine; leave an interval of at least one hour before taking the laxative. Concomitant use of other laxatives may potentiate the gastrointestinal side effects of Dulcolax.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe most commonly reported side effects during treatment with Dulcolax are abdominal pain and diarrhea. \u003cu\u003eImmune system disorders\u003c\/u\u003e: anaphylactic reactions, angioneurotic edema as well as other hypersensitivity reactions. \u003cu\u003eMetabolism and nutrition disorders\u003c\/u\u003e: dehydration. \u003cu\u003eNervous system disorders\u003c\/u\u003e: dizziness, syncope. The phenomena of dizziness and syncope that occur after taking bisacodyl appear to be attributable to a vasovagal response (resulting, for example, from abdominal pain, or the evacuation of feces). \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e: abdominal cramps, abdominal pain, diarrhea, nausea, hematochezia (blood in stool), vomiting, abdominal discomfort, anorectal discomfort, colitis including ischemic colitis. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e \u003cu\u003eReporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: \u003c\/u\u003e \u003cu\u003ehttp:\/\/www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetta-reazione-avversa.\u003c\/u\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSymptoms\u003c\/u\u003e Excessive doses can cause abdominal pain and diarrhea, and significant losses of potassium and other electrolytes. Chronic overdose of Dulcolax, as with other laxatives, can cause chronic diarrhea, abdominal pain, hypokalemia, secondary hyperaldosteronism and kidney stones. Renal tubular injury, metabolic alkalosis, and muscle weakness secondary to hypokalemia have also been described in association with chronic laxative abuse. Also see what is reported in the paragraph “Special warnings and precautions for use” regarding the abuse of laxatives. \u003cu\u003eTreatment\u003c\/u\u003e If action is taken within a short time of ingesting the oral form of Dulcolax, absorption can be reduced or avoided by inducing vomiting or gastric lavage. Fluid and electrolyte losses must be replaced. This is especially important in elderly and young patients. The administration of spasmolytics may be useful.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e There are no adequate and well-controlled studies on the use of the medicine during pregnancy. Therefore, although unwanted or toxic effects have never been reported during pregnancy, like all medicines, Dulcolax must be used only if necessary, under the direct supervision of a doctor, after evaluating the expected benefit for the mother in relation to the possible risk for the fetus. \u003cu\u003eFertility\u003c\/u\u003e No studies have been conducted to investigate the effects on human fertility. \u003cu\u003eBreastfeeding\u003c\/u\u003e Clinical data demonstrate that neither the active form of bisacodyl BHPM, bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), nor its glucuronic derivatives are excreted in breast milk, however the medicine should only be used if necessary, under direct medical supervision, after evaluating the expected benefit for the mother in relation to the possible risk for the infant.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo studies on the effects on the ability to drive and use machines have been performed. However, patients should be informed that due to vasovagal response (e.g., abdominal spasm), dizziness and\/or syncope may occur. If patients experience abdominal spasm they should avoid potentially dangerous activities such as driving or using machinery.\u003c\/p\u003e","brand":"Opella Healthcare","offers":[{"title":"Default Title","offer_id":51131302641991,"sku":"008997025","price":8.46,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/opella-healthcare-italy-srl-dulcolax-adulti-10mg-6-supposte-farmacia-dottor-tili-1213792177.jpg?v=1767134627"},{"product_id":"guttalax-7-5mg-ml-gocce-orali-15ml","title":"Guttalax 7.5mg\/ml oral drops 15ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term treatment of occasional constipation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e1 ml (15 drops) of solution contains: Active ingredient: sodium picosulphate 7.5 mg. Excipient with known effects: Sorbitol (E420) 450 mg (see section 4.4). For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSodium benzoate, liquid sorbitol (E420), sodium citrate, citric acid monohydrate, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGuttalax is contraindicated in patients with: • Hypersensitivity to the active substance and to any excipients, listed in paragraph 6.1; • Paralytic ileus or intestinal or biliary tract obstruction or stenosis; • Acute severe painful and\/or febrile abdominal conditions (such as appendicitis) associated with nausea and vomiting; • Severe state of dehydration; • Rare hereditary conditions of incompatibility with one of the excipients (see section 4.4). • Nausea or vomiting; • Acute inflammation of the gastrointestinal tract; • Rectal bleeding of unknown origin; • Gallstones; • Liver failure; • Pregnancy and breastfeeding (see section 4.6). Do not administer to children under 3 years of age (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following dosages are recommended: \u003cu\u003eAdults\u003c\/u\u003e In adults it is recommended to start with 7-8 drops in water per day and to decrease if the effect is excessive or to increase if the laxative effect is not achieved. In cases of stubborn constipation, up to 15-20 drops in water can be used. \u003cu\u003ePediatric population\u003c\/u\u003e In children (over 3 years): 2-3 drops in water per day. Do not exceed the recommended doses. It is advisable to initially use the minimum doses provided. The correct dose is the minimum sufficient to produce an easy evacuation of loose stools. When necessary, the dose can then be increased, but without ever exceeding the maximum indicated. Guttalax should preferably be taken in the evening to induce evacuation the following morning. Swallow together with an adequate amount of water. A diet rich in liquids favors the effect of the medicine. Laxatives should be used as infrequently as possible and for no longer than seven days. Use for longer periods of time requires a doctor's prescription after adequate evaluation of the individual case.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eKeep the bottle in the outer carton in order to protect the medicine from light. Validity after first opening: 12 months.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eWarnings\u003c\/u\u003e Like all laxatives, Guttalax should not be taken continuously every day or for long periods of time without investigating the cause of constipation. Prolonged and excessive use can lead to diarrhea, electrolyte imbalance and hypokalemia. Cases of dizziness and\/or syncope have been reported in patients taking Guttalax. The data available on these cases suggest that the events could be related to syncope from defecation (or syncope attributable to the effort of evacuation), or to a vasovagal response to abdominal pain related to constipation, and not necessarily to the intake of sodium picosulfate itself. The abuse of laxatives (frequent or prolonged use or with excessive doses) can cause persistent diarrhea with consequent loss of water, mineral salts (especially potassium) and other essential nutritional factors. In more severe cases, the onset of dehydration or hypokalemia is possible, which can cause cardiac or neuromuscular dysfunction, especially in case of simultaneous treatment with cardiac glycosides, diuretics or corticosteroids. The abuse of laxatives, especially contact laxatives (stimulant laxatives), can cause dependence (and, therefore, possible need to progressively increase the dosage), chronic constipation and loss of normal intestinal functions (intestinal atony). \u003cu\u003ePrecautions for use\u003c\/u\u003e In children aged between 3 and 12 years the medicine can only be used after consulting the doctor. The treatment of chronic or recurrent constipation always requires the intervention of a doctor for diagnosis, prescription of drugs and monitoring during the course of therapy. Consult your doctor when the need for the laxative derives from a sudden change in previous intestinal habits (frequency and characteristics of evacuations) that lasts for more than two weeks or when the use of the laxative fails to produce effects. It is also advisable for elderly people or those in poor health to consult their doctor before using the medicine. This medicinal product contains 450 mg of sorbitol in 1 ml (15 drops), equivalent to 600 mg of sorbitol in the maximum recommended daily dose of 1.33 ml (20 drops) in the treatment of an adult patient. Sorbitol is a source of fructose. Patients with hereditary fructose intolerance (HFI), a rare genetic disease, should not be given this medicine. This medicinal product contains less than 1 mmol sodium (23 mg) in 20 drops, the maximum recommended daily dose for an adult, i.e. it is essentially “sodium-free”.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLaxatives can reduce the residence time in the intestine, and therefore the absorption, of other drugs administered simultaneously orally. Therefore, avoid ingesting laxatives and other medicines at the same time: after taking a medicine, leave an interval of at least 2 hours before taking the laxative. Milk or antacids can change the effect of the medicine; leave an interval of at least one hour before taking the laxative. Continued use of Guttalax may increase patients' response to oral anticoagulants and change glucose tolerance. The concomitant use of diuretics or adrenocorticosteroids and excessive doses of Guttalax may lead to an increased risk of electrolyte imbalance. This imbalance, in turn, can lead to increased sensitivity to cardiac glycosides. Concomitant administration of antibiotics may reduce the laxative effect of Guttalax.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLike all medicines, Guttalax can cause side effects, although not everybody gets them. Adverse reactions are listed below by system organ class and frequency, according to the following categories: Very common ≥ 1\/10 Common ≥ 1\/100, \u003c 1\/10 Uncommon ≥ 1\/1,000, \u003c 1\/100 Rare ≥ 1\/10,000, \u003c 1\/1,000 Very rare \u003c 1\/10,000 Not known frequency cannot be defined on the basis of available data. \u003cu\u003eImmune system disorders\u003c\/u\u003e. Not known*: hypersensitivity. \u003cu\u003eNervous system disorders\u003c\/u\u003e. Uncommon: dizziness; Not known*: syncope. The phenomena of dizziness and syncope that occur after taking sodium picosulphate appear to be attributable to a vasovagal response (resulting, for example, from abdominal pain or the evacuation of feces). \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e. Very common: diarrhea; Common: abdominal cramps, abdominal pain and abdominal discomfort; Uncommon: vomiting, nausea. Occasionally: isolated cramping pain or abdominal colic, more frequent in cases of severe constipation. \u003cu\u003ePathologies of the skin and subcutaneous tissue\u003c\/u\u003e. Not known*: skin reactions such as angioedema, rash on taking the medicine, rash, itching. \u003ci\u003e*These adverse reactions were observed in post-marketing experience. At 95% probability, the frequency category is not greater than uncommon, but could be lower. A precise estimate of the frequency is not possible since these adverse reactions did not occur in 1020 patients in clinical trials\u003c\/i\u003e. \u003cu\u003eReporting of side effects\u003c\/u\u003e If you get any side effects, including any not listed in this leaflet, contact your doctor or pharmacist. Undesirable effects can also be reported directly via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse. Reporting side effects helps provide more information on the safety of this medicine\u003ci\u003e.\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSigns and symptoms\u003c\/u\u003e Following the intake of high doses of the drug, the following may occur: watery stools (diarrhoea), abdominal cramps and a significant loss of fluids, potassium and other electrolytes. Cases of colonic mucosal ischemia have been reported with doses of Guttalax considerably higher than the recommended dosage for the treatment of occasional constipation. Guttalax, like other laxatives, in case of overdose causes chronic diarrhea, abdominal pain, hypokalemia, secondary hyperaldosteronism and kidney stones. In association with chronic laxative abuse, renal tubular injury, metabolic alkalosis and muscle weakness secondary to hypokalemia have also been described. Also see what is reported in the paragraph “Special warnings and precautions for use” regarding the abuse of laxatives. \u003cu\u003eTreatment\u003c\/u\u003e If action is taken within a short time of ingesting Guttalax, absorption can be reduced or avoided by inducing vomiting or gastric lavage. Fluid and electrolyte losses must be replaced. This is especially important in the elderly and young people. The administration of spasmolytics may be useful.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eFertility\u003c\/u\u003e No studies have been conducted to evaluate the effects on human fertility. Non-clinical studies have revealed no effects on fertility (see section 5.3). \u003cu\u003ePregnancy\u003c\/u\u003e There are no adequate and well-controlled studies on the use of the medicine during pregnancy. Long experience has shown no evidence of unwanted or harmful effects during pregnancy. Although toxic effects have never been reported during pregnancy, the medicine must be used only if necessary, under the direct supervision of a doctor, after evaluating the expected benefit for the mother in relation to the possible risk for the fetus. \u003cu\u003eBreastfeeding\u003c\/u\u003e Clinical data demonstrate that neither the active fraction of sodium picosulphate, bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), nor the conjugated form (its glucuronic derivatives), are excreted in measurable quantities in breast milk. However, the medicine must be used only if necessary, under the direct supervision of a doctor, after evaluating the expected benefit for the mother in relation to the possible risk for the infant.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince no specific studies have been carried out, there are no known inhibitory effects of Guttalax that would compromise the ability to drive and use machinery. However, patients should be informed that due to vasovagal response (e.g., abdominal spasm), dizziness and\/or syncope may occur. If patients experience abdominal spasm they should avoid potentially dangerous activities such as driving or using machinery.\u003c\/p\u003e","brand":"Opella Healthcare","offers":[{"title":"Default Title","offer_id":51131350286663,"sku":"020949020","price":10.36,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/opella-healthcare-italy-srl-guttalax-7-5mg-ml-gocce-orali-15ml-farmacia-dottor-tili-1213791960.jpg?v=1767149908"},{"product_id":"alaxa-5mg-20-compresse-gastroresistenti","title":"Alaxa 5mg 20 gastro-resistant tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term treatment of occasional constipation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach gastro-resistant tablet contains: Active ingredient: bisacodyl 5 mg; Excipients with known effects: lactose monohydrate, sucrose, carboxymethylcellulose \u003cb\u003esodium\u003c\/b\u003e. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eTablet core\u003c\/i\u003e: \u003cb\u003elactose monohydrate\u003c\/b\u003e, corn starch, magnesium stearate, gelatin. \u003ci\u003eGastro-resistant film-coating\u003c\/i\u003e: diethyl phthalate, cellulose acetophthalate, talc. \u003ci\u003eSugary coating\u003c\/i\u003e: acacia, \u003cb\u003esucrose\u003c\/b\u003e, carboxymethylcellulose\u003cb\u003e sodium\u003c\/b\u003e, macrogol 6000, titanium dioxide, calcium carbonate, talc.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hypersensitivity to the active substance or to other chemically related substances or to any of the excipients listed in paragraph 6.1. - Children under 3 years of age. - Generally contraindicated during pregnancy and breastfeeding (see section 4.6). - Subjects with acute abdominal pain or pain of unknown origin, nausea or vomiting, intestinal obstruction or stenosis, rectal bleeding of unknown origin, severe dehydration, acute surgical abdomen, appendicitis, gastroenteritis.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e: 2 tablets per day; in particularly stubborn cases, 3 tablets. \u003ci\u003ePediatric population\u003c\/i\u003e. \u003cu\u003eChildren aged between 3 and 12 years\u003c\/u\u003e: 1-2 tablets per day (0.3 mg\/kg) under direct medical supervision. The correct dose is the minimum sufficient to produce an easy evacuation of loose stools. It is advisable to initially use the minimum doses provided. When necessary, the dose can then be increased, but without ever exceeding the maximum indicated. Laxatives should be used as infrequently as possible and for no longer than seven days. Use for longer periods of time requires a doctor's prescription after adequate evaluation of the individual case. \u003cu\u003eMethod of administration\u003c\/u\u003e: The tablets should be swallowed whole, without chewing, together with an adequate quantity of water (a large glass). A diet rich in liquids favors the effect of the medicine. The tablets should preferably be administered after the evening meal, so that the effect of the laxative, which occurs after 10-12 hours, does not disturb sleep. If taken on an empty stomach, the laxative effect occurs within approximately 5 hours. Take ALAXA at ​​least 1 hour after taking milk or antacids and at least two hours after taking other medicines orally.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicine does not require any particular storage temperature. Store in the original packaging, to protect the medicine from moisture.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAbuse of laxatives (frequent or prolonged use or with excessive doses) can cause persistent diarrhea with consequent loss of water, mineral salts (especially potassium) and other essential nutritional factors. In more severe cases, the onset of dehydration or hypokalemia is possible, which can cause cardiac or neuromuscular dysfunction, especially in case of simultaneous treatment with cardiac glycosides, diuretics or corticosteroids. Furthermore, the abuse of laxatives, especially contact laxatives (stimulant laxatives), can cause dependence (and therefore the possible need to progressively increase the dosage), chronic constipation and loss of normal intestinal functions (intestinal atony). Frequent or prolonged use of the medicine must be avoided as it can cause addiction and atonic colitis. The treatment of chronic or recurrent constipation always requires the intervention of a doctor for diagnosis, prescription of drugs and monitoring during the course of therapy. Caution is recommended if the need for the laxative derives from a sudden change in previous intestinal habits (frequency and characteristics of evacuations) that lasts for more than two weeks; when rectal bleeding is present; when the use of the laxative fails to produce effects or when the patient suffers from diabetes mellitus, hypertension or heart disease. It is also advisable for elderly people or those in poor health to consult their doctor before using the medicine. \u003ci\u003ePediatric population\u003c\/i\u003e: In children under 12 years of age the medicine can only be used after consulting a doctor. \u003cu\u003eImportant information about some excipients:\u003c\/u\u003e ALAXA contains: - lactose monohydrate: patients suffering from rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine; - sucrose: patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. - sodium: This medicinal product contains less than 1 mmol (23 mg) sodium per dose, i.e. essentially 'sodium-free'.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMilk or antacids can change the effect of the medicine; leave an interval of at least one hour before taking the laxative. Concomitant use of diuretics, cardiac glycosides or adrenocorticosteroids may promote electrolyte imbalance. Laxatives can reduce the residence time in the intestine, and therefore the absorption, of other drugs administered simultaneously orally. Therefore, avoid ingesting laxatives and other medicines at the same time: after taking a medicine, leave an interval of at least 2 hours before taking the laxative.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOccasionally: isolated cramping pain or abdominal colic. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eExcessive doses can cause abdominal pain and diarrhea; the resulting losses of fluids and electrolytes must be replaced. Muscle weakness and weight loss may occur. In case of accidental overdose, gastric lavage is indicated. See also what is reported in paragraph 4.4 regarding the abuse of laxatives.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no adequate and well-controlled studies on the use of the medicine during pregnancy or breastfeeding. Therefore, the medicine must be used only if necessary, under the direct supervision of a doctor, after evaluating the expected benefit for the mother in relation to the possible risk for the fetus or infant.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no limitations. However, those carrying out an activity that requires vigilance should use caution.\u003c\/p\u003e","brand":"Angelini Acraf","offers":[{"title":"Default Title","offer_id":51131368341831,"sku":"009262015","price":7.51,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-a-c-r-a-f-spa-alaxa-5mg-20-compresse-gastroresistenti-farmacia-dottor-tili-1213791893.jpg?v=1767150208"},{"product_id":"tamarine-8-0-39-marmellata-vasetto-260g","title":"Tamarine 8% + 0.39% jam jar 260g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term treatment of occasional constipation\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of product contains: \u003cb\u003eActive ingredients:\u003c\/b\u003e Cassia Angustifolia 8 g - Cassia fistula 0.39 g. \u003cu\u003eExcipients with known effects\u003c\/u\u003e: sucrose, sodium methyl parahydroxybenzoate, sodium hydroxide For the complete list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTamarindus indica soft extract, coriandrum sativum powder, glycyrrhiza glabra dry extract, sodium methyl parahydroxybenzoate, mirabella essence, sodium hydroxide (for pH adjustment), citric acid (for flavor adjustment), jam (sucrose, fruit, tartaric acid, potassium sorbate, water).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDiabetes. Hypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. Laxatives are contraindicated in subjects with acute abdominal pain or pain of unknown origin, nausea or vomiting, intestinal obstruction or stenosis, rectal bleeding of unknown origin, severe dehydration. Children under 10 years old. Pregnancy and breastfeeding (see p. 4.6).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe correct dose is the minimum sufficient to produce an easy evacuation of loose stools. It is advisable to use the minimum doses initially. When necessary, the dose can then be increased, but without ever exceeding the indicated one. Take preferably in the evening. \u003cb\u003eAdults: \u003c\/b\u003e1 teaspoon. \u003cb\u003eChildren over 10 years old\u003c\/b\u003e: ¼ teaspoon. Laxatives should be used as infrequently as possible and for no longer than seven days. Use for longer periods of time requires a doctor's prescription after adequate evaluation of the individual case. Swallow together with an adequate quantity of water (a large glass). A diet rich in liquids favors the effect of the medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store above 25°C. Keep container tightly closed. For storage conditions after first opening, see paragraph 6.3.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003cu\u003eWarnings\u003c\/u\u003e \u003c\/b\u003e Abuse of laxatives (frequent or prolonged use or with excessive doses) can cause persistent diarrhea with consequent loss of water, mineral salts (especially potassium) and other essential nutritional factors. In more severe cases, the onset of dehydration or hypokalemia is possible which can cause cardiac or neuromuscular dysfunction, especially in case of simultaneous treatment with cardiac glycosides, diuretics or corticosteroids. The abuse of laxatives, especially contact laxatives (stimulant laxatives), can cause dependence (and, therefore, possible need to progressively increase the dosage), chronic constipation and loss of normal intestinal functions (intestinal atony). \u003cb\u003e \u003cu\u003ePrecautions for use \u003c\/u\u003e \u003c\/b\u003e The treatment of chronic or recurrent constipation always requires the intervention of a doctor for diagnosis, prescription of drugs and monitoring during the course of therapy. Consult your doctor when the need for the laxative derives from a sudden change in previous intestinal habits (frequency and characteristics of evacuations) that lasts for more than two weeks or when the use of the laxative fails to produce effects. It is also advisable for elderly people or those in poor health to consult their doctor before using the medicine. \u003cb\u003eTamarine contains sucrose.\u003c\/b\u003e Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine \u003cb\u003eTamarine contains sodium methyl parahydroxybenzoate.\u003c\/b\u003e May cause allergic reactions (even delayed). \u003cb\u003eTamarine contains less than 1 mmol (23 mg) sodium per serving (1 teaspoon)\u003c\/b\u003e, i.e. essentially 'sodium-free'.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLaxatives can reduce the residence time in the intestine, and therefore the absorption, of other drugs administered simultaneously orally. Therefore, avoid ingesting laxatives and other medicines at the same time: after taking a medicine, leave an interval of at least 2 hours before taking the laxative. Milk or antacids can change the effect of the medicine; leave an interval of at least one hour before taking the laxative. Concomitant use of other drugs that induce hypokalemia (e.g. diuretics, adrenocorticosteroids and licorice) may increase electrolyte imbalance. Hypokalemia (resulting from abuse of laxatives taken for a long time) enhances the action of cardiac glycosides and interferes with antiarrhythmic drugs, with other drugs that induce the return to sinus rhythm (quinidine) and with drugs that induce prolongation of the Q-T interval.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicine may occasionally cause: isolated cramping pain or abdominal colic, more frequent in cases of severe constipation. With the use of this medicine, the urine sometimes turns slightly yellow-brown or red. This coloring is simply due to the presence of senna components in the urine and is not clinically significant. Adverse reactions are listed below by system organ class and frequency. Frequencies are defined as: very common (≥ 1\/10), common (≥ 1\/100, \u003c 1\/10); uncommon (≥ 1\/1,000, \u003c 1\/100); rare (≥ 1\/10,000; \u003c 1\/1,000); very rare (\u003c 1\/10,000), or not known (frequency cannot be estimated from the available data). \u003cb\u003eTable 4-1 Undesirable effects in the post-marketing experience\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eImmune system disorders (not known) - Adverse event: Hypersensitivity reactions\u003c\/p\u003e\n\u003cp\u003eMetabolism and nutrition disorders (not known) - Adverse event: Hyperaldosteronism, Hypocalcemia, Hypomagnesemia, Dehydration, Hypokalemia, Hyponatremia, Decreased blood electrolytes.\u003c\/p\u003e\n\u003cp\u003eVascular disorders (not known) - Adverse event: Hypotension.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders (not known) - Adverse event: Megacolon, Diarrhea, Nausea, Abdominal discomfort.\u003c\/p\u003e\n\u003cp\u003eMusculoskeletal system and connective tissue disorders (not known) - Adverse event: Myopathy.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders (not known) - Adverse event: Kidney problems, Chromaturia.\u003c\/p\u003e\n\u003cp\u003eSystemic disorders and conditions relating to the site of administration (not known) - Adverse event: Fatigue, Tolerance to the drug (see Warnings and Precautions for use).\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eExcessive doses can cause abdominal pain and diarrhea; the resulting losses of fluids and electrolytes must be replaced with fluid intake. Treatment: discontinuation of the drug. Also see what is reported in the paragraph “Special warnings and precautions for use” regarding the abuse of laxatives.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no adequate and well-controlled studies on the use of the medicine during pregnancy or breastfeeding. Therefore, since anthraquinone laxatives may be excreted in breast milk, breastfeeding mothers should avoid taking Tamarine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known effects on the ability to drive and use machines.\u003c\/p\u003e","brand":"Haleon","offers":[{"title":"Default Title","offer_id":51131368407367,"sku":"021528157","price":18.76,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/haleon-italy-srl-tamarine-8-0-39-marmellata-vasetto-260g-farmacia-dottor-tili-1213791898.jpg?v=1767150189"},{"product_id":"regolint-9-7-g-20-bustine-polvere-per-soluzione-orale","title":"Regolint 9.7 g 20 sachets powder for oral solution","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term treatment of occasional constipation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eOne sachet contains\u003c\/u\u003e: \u003cu\u003eActive ingredient\u003c\/u\u003e: macrogol 4000 g 9,736. For the complete list of excipients see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAcesulfame potassium, banana flavour.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to macrogol (polyethylene glycol) or to any of the excipients; severe inflammatory bowel disease (such as ulcerative colitis, Crohn's disease) or toxic megacolon, associated with symptomatic stricture; perforation or risk of perforation of the digestive tract; ileus or suspected intestinal obstruction; acute abdominal pain or pain of unknown origin; nausea or vomiting, marked accentuation or reduction of peristalsis, rectal bleeding; severe state of dehydration.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eAdults and children over 8 years of age and weighing over 20 kg\u003c\/i\u003e The daily dose must be adapted based on the clinical effect obtained and can vary from one sachet every other day (especially in children) up to 2 sachets per day. Do not exceed the maximum daily dosage of 20 g of macrogol. The indicated dose should be adjusted based on individual response. The correct dose is the minimum sufficient to produce an easy evacuation of loose stools. It is advisable to initially use the minimum doses provided. When necessary, the dose can then be increased, but without ever exceeding the maximum indicated. The daily dose can be taken in one or two fractions, between meals. If you need to take a sachet, it must be taken in the morning. If you need to take multiple sachets, you will need to divide the doses between morning and evening. The effect of REGOLINT manifests itself in the 24-48 hours following its administration. Sometimes it can take two days (or more) before you get the desired effect. In this case, continue the treatment keeping in mind, however, that laxatives must be used as infrequently as possible and for no more than seven days. Use for longer periods of time requires a doctor's prescription after adequate evaluation of the individual case. In children, in the absence of clinical data on administration periods exceeding three months, treatment should not exceed three months. Dissolve the contents of one sachet in at least 125 ml (equal to a glass) of water. Do not add other ingredients. It is preferable to drink the entire quantity quite quickly (within a few minutes) avoiding sipping it for a long time. A diet rich in liquids favors the effect of the medicine. The regularization of intestinal motility induced by the treatment must be maintained with a healthy lifestyle and correct nutrition.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore in the original package to protect the medicine from moisture.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003ci\u003eWarnings\u003c\/i\u003e \u003c\/b\u003e Efficacy data in children under 2 years of age are limited. The treatment of constipation with any medicine is only an adjunct to a healthy lifestyle and correct nutrition, for example: increased intake of liquids and vegetable fibres, appropriate physical activity and restoration of intestinal motility. Before starting treatment, organic diseases must be excluded. Laxatives should not be used by subjects with acute abdominal pain or pain of unknown origin, nausea or vomiting, marked accentuation or reduction of peristalsis, rectal bleeding. The presence of one or more of these symptoms or signs requires an adequate diagnostic investigation by the doctor in order to exclude one of the pathological conditions that contraindicate the use of laxatives (for example: obstruction or suspected intestinal obstruction, intestinal stenosis or perforation, paralytic ileus, serious inflammatory diseases of the intestine). After a 3-month course of treatment, full clinical supervision of constipation should be performed. The abuse of laxatives (frequent or prolonged use or with excessive doses) can cause persistent diarrhea with consequent loss of water, mineral salts (especially potassium) and other essential nutritional factors. In more severe cases, the onset of dehydration or hypokalemia is possible which can cause cardiac or neuromuscular dysfunction, especially in case of simultaneous treatment with cardiac glycosides, diuretics or corticosteroids. Caution should be exercised in the elderly, in patients with hepatic insufficiency, renal insufficiency, heart failure. In these cases it is advisable to periodically check serum electrolyte levels. The abuse of laxatives, especially contact laxatives (stimulant laxatives), can cause dependence (and, therefore, possible need to progressively increase the dosage), chronic constipation and loss of normal intestinal functions (intestinal atony). REGOLINT, not containing any sugar or polyol, can be taken by diabetic patients or those undergoing a galactose-free regime. \u003cb\u003e \u003ci\u003ePrecautions for use\u003c\/i\u003e \u003c\/b\u003e In children the medicine can only be used after consulting a doctor. The treatment of chronic or recurrent constipation always requires the intervention of a doctor for diagnosis, prescription of drugs and monitoring during the course of therapy. Consult your doctor when the need for the laxative arises from a sudden change in previous intestinal habits (frequency and characteristics of evacuations) that lasts for more than two weeks or when the use of the laxative fails to produce effects. It is also advisable for elderly people or those in poor health to consult their doctor before using the medicine. Very rare cases of hypersensitivity reactions (rash, urticaria, edema) have been reported with some macrogol-containing medicinal products, including exceptional cases of anaphylactic shock. In these cases, stop taking the medicine and consult a doctor immediately.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLaxatives can reduce the residence time in the intestine and therefore the absorption of other drugs administered simultaneously orally. Therefore, avoid ingesting laxatives and other drugs at the same time: after taking a medicine, leave an interval of at least two hours before taking the laxative. Caution should be used when Regolint is used with drugs with a narrow therapeutic index (e.g. antiepileptics and immunosuppressive agents). The use of licorice increases the risk of hypokalemia.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse drug reactions are listed by frequency using the following frequency classes: very common (≥ 1\/10), common (≥ 1\/100, \u003c 1\/10), uncommon (≥1\/1,000, \u003c1\/100), rare (≥1\/10,000, \u003c1\/1,000), very rare (\u003c1\/10,000) and not known (frequency cannot be estimated). based on available data). \u003cu\u003eAdults\u003c\/u\u003e: The side effects listed in the following table were reported during clinical trials involving 600 adult patients and from post-marketing data. The reported adverse reactions are usually mild in intensity and transient, and mainly affect the gastrointestinal system. In case of hypersensitivity reactions, stop taking the medicine and consult a doctor immediately.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eCommon - Adverse reactions: Abdominal pain.\u003c\/p\u003e\n\u003cp\u003eCommon - Adverse reactions: Abdominal distension.\u003c\/p\u003e\n\u003cp\u003eCommon - Adverse reactions: Diarrhoea.\u003c\/p\u003e\n\u003cp\u003eCommon - Adverse reactions: Nausea.\u003c\/p\u003e\n\u003cp\u003eUncommon - Adverse reactions: Vomiting.\u003c\/p\u003e\n\u003cp\u003eUncommon - Adverse reactions: Urgent evacuation.\u003c\/p\u003e\n\u003cp\u003eUncommon - Adverse reactions: Faecal incontinence.\u003c\/p\u003e\n\u003cp\u003eUncommon - Adverse reactions: Rectal irritation.\u003c\/p\u003e\n\u003cp\u003eMetabolism and nutrition disorders.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse reactions: Electrolyte imbalance (hyponatremia, hypokalemia).\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse reactions: Dehydration (particularly in the elderly).\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare - Adverse reactions: Hypersensitivity reactions (pruritus, rash, urticaria, edema, face edema, angioedema, dyspnoea, anaphylactic shock).\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePediatric population\u003c\/u\u003e: The side effects listed in the table below were reported during clinical trials involving 147 children aged 6 months to 15 years, and from post-marketing data. As in the case of adults, the reported adverse reactions are usually mild in intensity and transient, and mainly affect the gastrointestinal system. In case of hypersensitivity reactions, stop taking the medicine and consult a doctor immediately.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eCommon - Adverse reactions: Abdominal pain.\u003c\/p\u003e\n\u003cp\u003eCommon - Adverse reactions: Diarrhoea*.\u003c\/p\u003e\n\u003cp\u003eUncommon - Adverse reactions: Vomiting.\u003c\/p\u003e\n\u003cp\u003eUncommon - Adverse reactions: Abdominal distension.\u003c\/p\u003e\n\u003cp\u003eUncommon - Adverse reactions: Nausea.\u003c\/p\u003e\n\u003cp\u003eUncommon - Adverse reactions: Rectal irritation.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eNot known - Adverse reactions: Hypersensitivity\u003c\/p\u003e\n\u003cp\u003e* Diarrhea can cause perianal pain \u003ci\u003eReporting of suspected adverse reactions\u003c\/i\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOverdose causes diarrhea which disappears with temporary interruption of treatment or reduction of the dose. Excessive fluid loss caused by diarrhea or vomiting may require correction of the electrolyte imbalance. Excessive doses can cause abdominal pain. Cases of aspiration have been reported during administration of large volumes of polyethylene glycol and electrolytes with a nasogastric tube. Children with neurological impairment who suffer from oromotor dysfunction are particularly at risk for aspiration. Also see what is reported in the paragraph \"Special warnings and precautions for use\" regarding the abuse of laxatives.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no adequate and well-controlled studies on the use of the medicine during pregnancy or breastfeeding. Therefore the medicine must be used only if necessary, under the direct supervision of the doctor, after having evaluated the expected benefit for the mother in relation to the possible risk for the fetus or infant.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo studies on the effects on the ability to drive and use machines have been performed.\u003c\/p\u003e","brand":"Baldacci","offers":[{"title":"Default Title","offer_id":51730202788167,"sku":"038204020","price":14.35,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/baldacci-regolint-9-7-g-20-bustine-polvere-per-soluzione-orale-farmacia-dottor-tili-1258975917.jpg?v=1789560579"},{"product_id":"casenlax-10-g-20-bustine-polvere-per-soluzione-orale","title":"Casenlax 10 g 20 sachets powder for oral solution","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptomatic treatment of constipation in adults and children aged 8 years and older. An organic disorder must be excluded before starting treatment. Casenlax must remain a temporary treatment adjuvant to an appropriate lifestyle and diet for constipation, with a maximum treatment cycle of 3 months in children. If symptoms persist despite associated dietary measures, a different underlying cause should be suspected and treated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach sachet contains 10 g of macrogol 4000. Excipients with known effects: 0.0000018 mg sulfur dioxide (E220) per sachet and less than 1 mmol (23 mg) sodium per sachet. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSodium saccharin (E954), apple flavour* *Composition of apple flavour: Natural flavour, maltodextrin, gum arabic E414, sulfur dioxide E220, alpha tocopherol E307.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. - Severe inflammatory bowel disease (such as ulcerative colitis, Crohn's disease) or toxic megacolon, associated with symptomatic stricture. - Perforation of the digestive system or risk of perforation of the digestive system. - Paralytic ileus or suspected intestinal obstruction. - Painful abdominal syndromes of an undetermined nature.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOral use \u003cu\u003eDosage\u003c\/u\u003e 1 to 2 sachets per day, preferably taken as a single dose in the morning. It is recommended to drink 125 ml of fluid (e.g. water) after each dose. The effect of Casenlax occurs within 24-48 hours after administration. The daily dose must be adapted according to the clinical effects and can vary from one sachet every other day (especially in children) up to 2 sachets per day. Treatment should be stopped gradually and restarted if constipation recurs. \u003ci\u003ePediatric population\u003c\/i\u003e 1 to 2 sachets per day, preferably taken as a single dose in the morning. It is recommended to drink 125 ml of fluid (e.g. water) after each dose. In children, treatment should not exceed 3 months due to the lack of clinical data in treatments lasting longer than 3 months. The regularization of intestinal motility induced by the treatment will be maintained by lifestyle and dietary measures. \u003cu\u003eMethod of administration\u003c\/u\u003e Each sachet should be dissolved in a glass of water (approximately 125 ml) just before use. The resulting solution will be clear and transparent like water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe treatment of constipation with any medicine is only an adjunct to a healthy lifestyle and diet, for example: - Increased intake of liquids and dietary fibre, - Adequate physical activity and re-education of intestinal motility. Due to the presence of sulfur dioxide Casenlax can rarely cause severe hypersensitivity reactions and bronchospasm. In case of diarrhoea, caution should be used in patients predisposed to water and\/or electrolyte balance disorders (e.g. elderly, patients with hepatic or renal impairment or patients being treated with diuretics) and electrolyte control should be considered. Hypersensitivity reactions (rash, urticaria and edema) have been reported with drugs containing macrogol (polyethylene glycol). Exceptional cases of anaphylactic shock have been reported. Casenlax contains a non-significant amount of sugars or polyols and can be prescribed to diabetic patients or patients following a galactose-free diet. This medicinal product contains less than 1 mmol (23 mg) sodium per sachet, i.e. essentially 'sodium-free'. Based on the mechanism of action of macrogol, fluid intake is recommended during treatment with this medicinal product (see section 5.1). The absorption of other medicinal products may be temporarily reduced due to the macrogol-induced increase in gastrointestinal transit rate (see section 4.5).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere is a possibility that the absorption of other medicines may be temporarily reduced while using Casenlax. The therapeutic effect of medicinal products with a narrow therapeutic index (e.g. antiepileptics, digoxin and immunosuppressive agents) may be particularly affected.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects are listed by frequency using the following categories: Very common (≥1\/10); common (≥1\/100, \u003c1\/10); uncommon (≥1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000); not known (frequency cannot be estimated from the available data). \u003cb\u003e \u003cu\u003eAdult population\u003c\/u\u003e:\u003c\/b\u003e The side effects listed in the following table were reported during clinical trials including 600 adult patients and in post-marketing experience. In general, adverse reactions were mild and transient and mainly affected the gastrointestinal system:\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eSystem organs: Very rare - Adverse reactions: Hypersensitivity reactions (pruritus, rash, facial edema, Quincke's edema, urticaria, anaphylactic shock).\u003c\/p\u003e\n\u003cp\u003eSystem organs: Not known - Adverse reactions: Erythema.\u003c\/p\u003e\n\u003cp\u003eMetabolism and nutrition disorders.\u003c\/p\u003e\n\u003cp\u003eSystem Organs: Not known - Adverse reactions: Electrolyte disturbances (hyponatremia, hypokalemia) and\/or dehydration, especially in elderly patients.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eSystem organs: Common - Adverse reactions: Abdominal pain and\/or distension, Diarrhoea, Nausea.\u003c\/p\u003e\n\u003cp\u003eSystem organs: Uncommon - Adverse reactions: Vomiting, Defecation urgency, Fecal incontinence.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003cu\u003ePediatric population:\u003c\/u\u003e \u003c\/b\u003e The side effects listed in the following table were reported during clinical trials involving 147 children aged between 6 months and 15 years and in post-marketing use. As in the adult population, adverse reactions were generally mild and transient and mainly concerned the gastrointestinal system:\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eSystem organs: Not known - Adverse reactions: Hypersensitivity reactions (anaphylactic shock, angioedema, urticaria, rash, pruritus).\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eSystem organs: Common - Adverse reactions: Abdominal pain, Diarrhoea*.\u003c\/p\u003e\n\u003cp\u003eSystem organs: Uncommon - Adverse reactions: Vomiting, Bloating, Nausea.\u003c\/p\u003e\n\u003cp\u003e* Diarrhea can cause perianal pain \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at \u003cu\u003ehttp:\/\/www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetta-reazione-avversa\u003c\/u\u003e.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOverdose can lead to diarrhea, abdominal pain and vomiting which disappear when treatment is stopped temporarily or the dosage is reduced. Excessive fluid loss due to diarrhea or vomiting may require correction of electrolyte imbalances. Cases of aspiration have been reported when large volumes of macrogol (polyethylene glycol) and electrolytes were administered via nasogastric tube. Neurologically compromised children who suffer from oromotor dysfunction are particularly at risk for aspiration.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Animal studies do not indicate direct or indirect harmful effects of reproductive toxicity (see section 5.3). Data relating to the use of Casenlax in pregnant women are limited (less than 300 pregnancy outcomes). Casenlax is not expected to cause any effects during pregnancy, since systemic exposure to Casenlax is negligible. Casenlax can be used during pregnancy. \u003cu\u003eBreastfeeding\u003c\/u\u003e There are no data on the excretion of Casenlax in breast milk. Macrogol 4000 is not expected to cause any effects on newborns\/infants, as systemic exposure to macrogol 4000 of breastfeeding women is negligible. Casenlax can be used during breastfeeding. \u003cu\u003eFertility\u003c\/u\u003e No fertility studies have been conducted with Casenlax; however, since macrogol 4000 is not significantly absorbed, no effects are expected.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCasenlax does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Casen Recordati","offers":[{"title":"Default Title","offer_id":51730205573447,"sku":"042583029","price":14.92,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/casen-recordati-casenlax-10-g-20-bustine-polvere-per-soluzione-orale-farmacia-dottor-tili-1254215771.jpg?v=1786736397"},{"product_id":"agiolax-granulato-400-g-confezione-con-cucchiaio-dosatore","title":"Agiolax granules 400 g pack with measuring spoon","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term treatment of occasional constipation in adults and adolescents over 12 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of granules contain \u003ci\u003eActive ingredients:\u003c\/i\u003e - Ispagula seed 52 g - Ispagula cuticle 2.2 g - Senna fruit 6.74 - 13.15 g equivalent to 300 mg of hydroxyanthracene derivatives calculated as sennoside B Excipients with known effects: sucrose For the complete list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTalc, gum arabic, cumin essence, sage essence, mint essence, liquid paraffin, solid paraffin, E 172, sucrose.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• hypersensitivity to the active substances or to any of the excipients listed in section 6.1 • sudden irregularity of intestinal functions that persists for more than 2 weeks • acute abdominal pain or of unknown origin • nausea or vomiting • intestinal obstruction • esophageal or gastrointestinal stricture • rectal bleeding of unknown origin • failure to defecate following the use of laxatives • severe state of dehydration • dysphagia, hiatal hernia or conditions which pose a risk of regurgitation • atony of the colon • megacolon • faecal impaction • children under 12 years of age • pregnancy and breast-feeding (see section 4.6) • Crohn's disease, ulcerative colitis and appendicitis\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDosage The correct dose is the minimum sufficient to produce an easy evacuation of soft stools. It is recommended to initially use the minimum doses envisaged. When necessary, the dose can be increased. Do not exceed the maximum recommended daily dose. \u003cstrong\u003eAdults and adolescents over 12 years:\u003c\/strong\u003e The recommended dose is 5 g or 10 g of granules (corresponding to 1 - 2 measuring spoons) once a day. 1-2 sachets of 5 g once a day. Do not exceed the maximum recommended daily dose. \u003cb\u003eChildren \u003c\/b\u003e Agiolax is contraindicated in children under 12 years of age (see section 4.3). A unit dose of 5 g of granules contains: 2.6 g of Ispagula seed 0.11 g of Ispagula cuticle 0.34 - 0.66 g of Senna fruit \u003cu\u003eMethod of administration\u003c\/u\u003e For oral use. The granules should not be chewed or dissolved, but must be placed on the tongue and swallowed, standing upright, drinking a large glass of water. Agiolax should always be taken with liquids. Without sufficient fluids, the product may swell and obstruct the pharynx or esophagus, creating a risk of suffocation (see section 4.4). It can be taken regardless of meals. Take preferably in the evening, one hour before bedtime. Use the graduated measuring spoon supplied with the package. \u003cu\u003eDuration of treatment\u003c\/u\u003e Laxatives should be used as infrequently as possible and should not be used for more than 7 days. If after 3 days no improvements are observed or abdominal pain or bowel irregularities arise, re-evaluate the clinical picture. Prolonged use should be established after adequate clinical evaluation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g, 250 g, 400 g container: Store below 25°C Sachets: Store below 30°C. Keep in the original packaging in order to protect the medicine from moisture.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eWarnings\u003c\/b\u003e Abuse of laxatives (frequent or prolonged use or with excessive doses) can cause persistent diarrhea with consequent loss of water, mineral salts (especially potassium) and other essential nutritional factors. In more severe cases, the onset of dehydration or hypokalemia is possible, which can cause cardiac or neuromuscular dysfunction especially in case of simultaneous treatment with some medicinal products (see section 4.5). The abuse of laxatives, especially contact laxatives (stimulant laxatives), can cause addiction (possible need to progressively increase the dosage), chronic constipation and loss of normal intestinal functions (intestinal atony). During treatment with Agiolax it is necessary to ingest a large quantity of water (6-8 glasses per day) to prevent the onset of intestinal obstruction. Agiolax should be used only if a therapeutic effect cannot be achieved by changing the diet or administering bulking laxatives. The use of laxatives concomitantly with thyroid hormones may make it necessary to adjust the dose of thyroid hormones. Given the risk of gastrointestinal obstruction, Agiolax should not be used together with medicinal products known to inhibit peristaltic movement (see section 4.5). After oral intake or skin contact Agiolax may cause hypersensitivity reactions (see section 4.8). Abdominal pain, spasms and diarrhea may occur, especially in the case of pre-existing irritable bowel syndrome (see section 4.8). These symptoms can also arise following overdose; in this circumstance it is necessary to reduce the dose (see section 4.9). Important information about some excipients Agiolax contains sucrose: patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypokalaemia (resulting from long-term abuse of laxatives) potentiates the effects of cardiac glycosides and interacts with antiarrhythmic medicinal products, medicinal products that induce sinus rhythm reversal (e.g. quinidine) and medicinal products that induce QT prolongation. Concomitant use of diuretics, corticosteroids and licorice root may increase electrolyte imbalance. Laxatives can reduce the residence time in the intestine, and therefore the absorption, of other drugs administered simultaneously orally (e.g. vitamin B12, coumarin derivatives, lithium and carbamazepine). Concomitant administration of antidiabetics may increase the risk of hypoglycemia. Avoid ingesting laxatives and other medicines at the same time: leave an interval of at least 2 hours before or after taking the laxative and another medicine. Agiolax may potentiate the risk of occlusion from opioid-induced reduced peristalsis (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects are reported according to system organ class according to MedDRA. Undesirable effects are listed using the MedDRA frequency convention: very common (≥1\/10); common (≥1\/100, \u003c1\/10); uncommon (≥ 1\/1000, \u003c 1\/100); rare ≥ 1\/10,000, \u003c 1\/1000); very rare (\u003c1\/10,000); not known (frequency cannot be estimated from the available data). Undesirable effects are presented in order of decreasing severity.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Rare (≥ 1\/10,000, ≤ 1\/1,000): Abdominal colic*, Flatulence, Abdominal distension, Gastrointestinal obstruction, Faecal impaction. Very rare (≤1\/10,000): Obstruction of the esophagus. Not known: Nausea, Vomiting, Diarrhoea.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders - Rare (≥ 1\/10,000, ≤ 1\/1,000): Chromaturia***. Not known: Albuminuria**, Haematuria**.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Not known: Hypersensitivity reactions, Anaphylactic reactions, Rash, Pruritus.\u003c\/p\u003e\n\u003cp\u003e*more frequently in case of severe constipation or irritable bowel syndrome; ** from prolonged use; *** this coloring is due to the presence of senna components in the urine and is not clinically significant. Furthermore, melanosis of the colon which recedes after discontinuation of the medicinal product has been reported. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eExcessive doses can cause abdominal spasms, abdominal pain, flatulence, intestinal obstruction and severe diarrhoea, in which case treatment should be suspended and the resulting losses of fluids and electrolytes must be replenished. Prolonged use of high doses of medicines containing anthraquinones may cause toxic hepatitis.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Use during pregnancy is contraindicated due to the known genotoxicity of anthraquinones contained in senna (see section 4.3). \u003cu\u003eBreastfeeding\u003c\/u\u003e Small quantities of active anthraquinone metabolites, such as rhein, are excreted in breast milk, therefore the use of Agiolax during breast-feeding is contraindicated (see section 4.3). \u003cu\u003eFertility\u003c\/u\u003e No fertility studies have been conducted.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAgiolax does not alter the ability to drive and use machines.\u003c\/p\u003e","brand":"Viatris Healthcare","offers":[{"title":"Default Title","offer_id":51730208358727,"sku":"023714037","price":15.72,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/viatris-healthcare-limited-agiolax-granulato-400-g-confezione-con-cucchiaio-dosatore-farmacia-dottor-tili-1213791076.jpg?v=1767154367"},{"product_id":"clisma-lax-133-ml-4-flaconi-soluzione-rettale","title":"Lax enema 133 ml 4 bottles rectal solution","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term treatment of occasional constipation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 ml contain 13.91 g of anhydrous monobasic sodium phosphate (NaH\u003csub\u003e2\u003c\/sub\u003ePO\u003csub\u003e4\u003c\/sub\u003e); 3.18 g of dibasic sodium phosphate (Na\u003csub\u003e2\u003c\/sub\u003eHPO\u003csub\u003e4\u003c\/sub\u003e). Excipients with known effects: sodium benzoate (100mg per 100ml) and methylparahydroxybenzoate (50mg per 100ml). For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSodium hydroxide, sodium benzoate, methyl parahydroxybenzoate, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e-Hypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. - acute abdominal pain or of unknown origin - nausea or vomiting - intestinal obstruction or stenosis or anorectal stenosis - intestinal sub-occlusion - mechanical ileus - paralytic ileus - inflammatory intestinal disorders and other conditions that can increase the absorption of the medicine - anal perforation - congenital or acquired megacolon - Hirschsprung's disease - rectal bleeding of unknown origin - acute haemorrhoidal crisis with pain and bleeding - severe state of dehydration - children under the age of twelve. Phosphates are contraindicated in patients with cardiac disorders, severe renal insufficiency or in the presence of hyperphosphatemia. Other preparations with sodium phosphates, including oral solutions or sodium phosphate tablets, should not be administered simultaneously (see section 4.5).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e Adults and adolescents (12-18 years): the entire dose of the bottle. \u003cu\u003eMethod of administration\u003c\/u\u003e Do not exceed the recommended doses. Laxatives should be used as infrequently as possible and for no longer than seven days. Use for longer periods of time requires a doctor's prescription after adequate evaluation of the individual case. Take preferably in the evening.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePediatric population\u003c\/u\u003e: The 133 ml bottle should not be used in children under 12 years of age. Abuse of laxatives (frequent or prolonged use or with excessive doses) can cause persistent diarrhea with consequent loss of water, mineral salts (especially potassium) and other essential nutritional factors. In more severe cases, the onset of dehydration or hypokalemia is possible which can cause cardiac or neuromuscular dysfunction, especially in case of simultaneous treatment with cardiac glycosides, diuretics or corticosteroids. Patients should be encouraged to drink fluids to help prevent dehydration, particularly patients with conditions that may predispose to dehydration, or those taking medications that may decrease the glomerular filtration rate, such as diuretics, angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin receptor blockers (sartans), or nonsteroidal anti-inflammatory drugs (NSAIDs). Since Clisma lax contains sodium phosphates, there is a risk of elevated serum sodium and phosphate levels and decreased calcium and potassium levels, and consequently hypernatraemia, hyperphosphataemia, hypocalcaemia and hypokalaemia, which may occur with clinical signs such as tetany and renal failure. Abuse of laxatives can cause dependence (and, therefore, possible need to progressively increase the dosage), chronic constipation and loss of normal intestinal functions (intestinal atony). Repeated use of laxatives can give rise to addiction or various types of damage. Prolonged use of a laxative to treat constipation is not recommended. The pharmacological treatment of constipation must be considered an adjuvant to the hygienic-dietary treatment (e.g. increase in vegetable fibers and liquids in the diet, physical activity and re-education of intestinal motility). The treatment of chronic or recurrent constipation always requires the intervention of a doctor for diagnosis, prescription of drugs and monitoring during the course of therapy. A careful evaluation by the doctor is essential when the need for the laxative derives from a sudden change in previous intestinal habits (frequency and characteristics of evacuations) that lasts for more than two weeks or when the use of the laxative fails to produce effects. Elderly people or those in poor health and patients with uncontrolled arterial hypertension, ascites, heart disease, changes in the rectal mucosa (ulcers, fissures) should consult their doctor before using the medicine. Patients should be advised to discontinue administration if resistance is encountered, as forcible administration of the enema may cause injury. In episodes of constipation, it is recommended first of all to correct eating habits by integrating the daily diet with an adequate intake of fiber and water. When using laxatives it is advisable to drink at least 6-8 glasses of water or other liquids a day to help soften the stool.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe systemic absorption of sodium phosphate rectal solution is limited, however in some conditions it may be increased and predispose to possible interactions with other drugs. The simultaneous intake of drugs that can have effects on electrolyte balance (such as diuretics, cortisone, calcium channel blockers, lithium) can facilitate the onset of hyperphosphatemia, hypercalcemia and hypernatremia. Patients taking drugs that can prolong the QT interval may be at greater risk of developing this adverse reaction if treated concomitantly with sodium phosphate. Since hypernatremia is associated with low lithium levels, the concomitant use of Enema lax and lithium may cause a reduction in serum lithium levels, with a decrease in efficacy. Concomitant use of calcium supplements or calcium-containing antacids may increase the risk of ectopic calcification. Other preparations with sodium phosphates, including oral solutions or sodium phosphate tablets, should not be administered simultaneously (see section 4.3).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBelow are the side effects of sodium phosphate organized according to the MedDRA system organic classification. There is insufficient data to establish the frequency of the individual effects listed. \u003ci\u003eImmune system disorders\u003c\/i\u003e Hypersensitivity reactions (e.g. urticaria) \u003ci\u003ePathologies of the skin and subcutaneous tissue\u003c\/i\u003e Blisters, itching, burning \u003ci\u003eGastrointestinal disorders\u003c\/i\u003e Isolated crampy pain or abdominal colic and diarrhea, with loss of fluids and electrolytes, more frequent in cases of severe constipation, as well as rectal irritation. Nausea, vomiting. \u003ci\u003eMetabolism and nutrition disorders\u003c\/i\u003e Hyperphosphatemia, hypokalemia, hypernatremia, hypocalcemia, and tissue calcification may rarely occur. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe effect most frequently observed following ingestion or rectal administration is gastrointestinal irritation (abdominal pain, nausea, vomiting, diarrhoea). Persistent diarrhea results in loss of water, mineral salts (especially potassium) and other essential nutritional factors. Fluid and electrolyte losses must be replaced. Electrolyte imbalances are characterized by the following symptoms: thirst, vomiting, weakness, edema, bone pain (osteomalacia) and hypoalbuminemia. In more severe cases, the onset of dehydration or hypokalemia is possible which can cause cardiac or neuromuscular dysfunction, especially in the case of simultaneous treatment with cardiac glycosides, diuretics or corticosteroids. Fluid and electrolyte losses must be replaced. Generally, conservative measures are sufficient; plenty of liquids must be given, especially fruit juices. See also what is reported in paragraph 4.4 regarding the abuse of laxatives. If a significant amount of phosphate is absorbed, hyperphosphatemia, hypocalcemia, and hypomagnesemia may occur. Alterations in fluid and electrolyte balance have been observed following oral, rectal and intravenous exposure. Severe hyperphosphatemia and hypocalcemia may cause tetany, convulsions, bradycardia, QT interval prolongation, arrhythmia, coma and cardiac arrest. Severe dehydration, hypernatremia, hypotension, metabolic acidosis, and tachycardia may also occur. The elderly, children and patients with renal insufficiency are at increased risk of toxic effects.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no adequate and well-controlled studies on the use of the medicine during pregnancy or breastfeeding. Therefore the medicine must be used only if necessary, under the direct supervision of the doctor, after having evaluated the expected benefit for the mother in relation to the possible risk for the fetus or infant.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe medicine does not alter the ability to drive or use machines. However, it is possible that side effects may occur during treatment, therefore it is good to know the reaction to the drug before driving vehicles or using machinery.\u003c\/p\u003e","brand":"Alfasigma","offers":[{"title":"Default Title","offer_id":51730212061511,"sku":"024995045","price":17.21,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/alfasigma-spa-clisma-lax-133-ml-4-flaconi-soluzione-rettale-farmacia-dottor-tili-1213791008.jpg?v=1767155829"},{"product_id":"verolax-3-g-6-monodose-soluzione-rettale","title":"Verolax 3 g 6 single-dose rectal solution","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eConstipation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eVerolax “6.75 g Adults Rectal Solution” 6 Single-dose Containers 9 G\u003c\/i\u003e: Each 9G single-dose container contains: \u003ci\u003eActive ingredient\u003c\/i\u003e: glycerin 6.75 g \u003ci\u003eVerolax “2.25 g Children Rectal Solution” 6 Single-dose Containers 3 G\u003c\/i\u003e: Each 3G single-dose container contains: \u003ci\u003eActive ingredient\u003c\/i\u003e: glycerin 2.25 g \u003ci\u003eVerolax “2.25 g Adult Suppositories” 18 Suppositories\u003c\/i\u003e:Each adult suppository contains: \u003ci\u003eActive ingredient\u003c\/i\u003e: glycerin 2.25 g \u003ci\u003eVerolax “1,375 g Children Suppositories” 18 Suppositories\u003c\/i\u003e: Each children's suppository contains: \u003ci\u003eActive ingredient\u003c\/i\u003e: glycerin 1.375 g \u003ci\u003eVerolax “0.675 g Infant Suppositories” 12 Suppositories\u003c\/i\u003e: Each infant suppository contains: \u003ci\u003eActive ingredient\u003c\/i\u003e: glycerin 0.675 g\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eRectal solution for adults and children:\u003c\/i\u003e Mallow fluid extract; Chamomile fluid extract; Wheat starch; Purified water. \u003ci\u003eSuppositories Adults, Children, Infants:\u003c\/i\u003e Sodium stearate, Sodium carbonate.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIndividual hypersensitivity confirmed towards the product. Anorectal diseases, hemorrhagic rectocolitis and inflammation of hemorrhoids. \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eRectal solution:\u003c\/i\u003e 1 or 2 single-dose containers in 24 hours. In case of stubborn constipation, no more than 2 doses can be introduced into the rectum at the same time. \u003ci\u003eSuppositories:\u003c\/i\u003e 1 suppository as needed. Do not exceed the recommended doses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo special precautions for storage.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe continuous use of laxatives can cause addiction or damage of various types. Do not use laxatives if abdominal pain, nausea and vomiting are present. If constipation is stubborn, consult your doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo interactions with other drugs have been found. \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe only effects that may be encountered are irritative, at the level of the rectal area. These are usually mild forms, which do not require medical intervention.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known symptoms of overdose.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBased on its chemical-physical properties, rectal glycerin can be usefully used during pregnancy or the puerperium.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTaking the drug does not alter the ability to drive or use machines.\u003c\/p\u003e","brand":"Angelini Acraf","offers":[{"title":"Default Title","offer_id":51730213273927,"sku":"026525042","price":5.21,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-a-c-r-a-f-spa-verolax-3-g-6-monodose-soluzione-rettale-farmacia-dottor-tili-1213791002.jpg?v=1767155951"}],"url":"https:\/\/www.dottortili.com\/en\/collections\/farmaci-lassativi-per-la-stitichezza.oembed","provider":"Farmacia Dottor Tili","version":"1.0","type":"link"}